{
  "entity_id": "B-002589",
  "folder": "Pharmaceutical-Benefits-Advisory-Committee",
  "name": "Pharmaceutical Benefits Advisory Committee",
  "type": "Statutory Body",
  "jurisdiction": "Commonwealth",
  "portfolio": "Health, Disability and Ageing",
  "website": "http://www.pbs.gov.au/info/industry/listing/participants/pbac",
  "data_status": "partial",
  "completeness": {
    "has_strategy_brief": false,
    "has_strategy_structured": true,
    "has_vision": false,
    "has_kpi_targets": false,
    "has_kpi_results": false,
    "has_strategy_overview": true,
    "has_legislation_text": true,
    "has_legislation_structured": false,
    "has_global_initiatives_text": false,
    "has_ideas": true,
    "has_artifacts": true,
    "n_ideas": 12,
    "n_legislation": 0,
    "n_artifacts": 4,
    "n_kpi_targets": 0,
    "n_kpi_results": 0,
    "n_outcomes": 0,
    "verified_own_data": true
  },
  "strategy_profile": {
    "status": "needs_review",
    "confidence": "medium",
    "summary": "",
    "official_site_url": "http://www.pbs.gov.au/info/industry/listing/participants/pbac",
    "source_documents": [
      {
        "type": "pb",
        "title": "Schedule of Pharmaceutical Benefits (Summary of Changes) (PDF 2MB)",
        "url": "http://www.pbs.gov.au/publication/schedule/2026/05/2026-05-01-general-soc.pdf",
        "period": "2026",
        "confidence": "medium"
      },
      {
        "type": "pb",
        "title": "December 2025 PBAC Intracycle Meeting (PDF 254KB)",
        "url": "http://www.pbs.gov.au/industry/listing/elements/pbac-meetings/agenda/pdf/2025/PBAC-Intracycle-meeting-agenda-DECEMBER-2025.pdf",
        "period": "2025",
        "confidence": "medium"
      }
    ],
    "purpose": null,
    "vision": null,
    "strategic_priorities": [],
    "values": [],
    "outcomes": [],
    "performance_measures": [],
    "document_alignment_terms": {
      "must_support": [],
      "watch_terms": [],
      "avoid_claiming_without_evidence": []
    },
    "review_note": "Structured strategy exists but is incomplete."
  },
  "strategy_brief_md": null,
  "strategy_overview_evidence_md": null,
  "internal_strategy_evidence_md": "# Pharmaceutical Benefits Advisory Committee - Strategy, Performance, and Operating Profile\n\n**Generated at**: 2026-05-09T22:19:03.188798+00:00\n**Entity ID**: B-002589\n**Entity type**: Statutory Body\n**Jurisdiction**: Commonwealth\n**Portfolio**: Health, Disability and Ageing\n**Website**: http://www.pbs.gov.au/info/industry/listing/participants/pbac\n\n> Draft generated from scraped source material. Treat this as an evidence pack for editorial review, not a final judgement.\n\n## Source Coverage\n\n| Source type | Count |\n|---|---:|\n| other-pdfs | 2 |\n| pages | 38 |\n| pbs | 2 |\n\n## Executive Readout\n\n### Purpose\n\n- Document and retain in the patient's medical records the qualifying baseline laboratory reading for the purpose of assessing\nresponse to treatment under the 'Continuing treatment' restriction.\nobeticholic acid 5 mg tablet, 30\n12623J Max.Qty Packs No. of Rpts Premium $ DPMQ $ MRVSN $ Brand Name and Manufacturer\n1 5 ..\n  Source: `other-pdfs/2026-05-01-general-schedule-Volume-1.pdf (http://www.pbs.gov.au/publication/schedule/2026/05/2026-05-01-general-schedule-Volume-1.pdf)`\n- If restriction is lengthy\nnew listing/change to listing) it may be paraphrased.)\nRAXTOZINAMERAN\nI.M. injection, suspension for injection containing\nraxtozinameran 30 micrograms\nNew vaccine - Prevention of\nTo request a National Immunisation Program listing for the\nprevention of coronavirus disease 2019 (COVID-19) caused by the\nComirnaty® Omicron XBB.1.5 coronavirus disease 2019 (COVID-19)\nSARS-CoV-2 virus in adults aged ≥ 18 years at increased risk of\ncaused by SARS-CoV-2\nsevere COVID-19 disease.\n  Source: `pbs/2025.pdf (http://www.pbs.gov.au/industry/listing/elements/pbac-meetings/agenda/pdf/2025/PBAC-Intracycle-meeting-agenda-DECEMBER-2025.pdf)`\n- The aim of the National Medicines Policy is to meet medication and related service\nneeds, so that both optimal health outcomes and economic objectives are achieved.\n  Source: `pages/about.html (http://www.pbs.gov.au/info/about-the-pbs)`\n- Dose modification (where dose escalation occurs during initial treatment)\nIf an adequate clinical response has not been achieved after at least 1 month and up to 3 months of initial treatment, the\ndose may be increased to 120 micrograms/kg/day (maximum of 7,200 micrograms per day) through the dose modification\ntreatment phase for up to a total period of 6 months from the date of treatment commencement with odevixibat.\n  Source: `other-pdfs/2026-05-01-general-schedule-Volume-1.pdf (http://www.pbs.gov.au/publication/schedule/2026/05/2026-05-01-general-schedule-Volume-1.pdf)`\n\n### Role and Functions\n\n- A retrospective diagnosis of ADHD for the purposes of administering this restriction is:\n(i) the presence of pre-existing childhood symptoms of ADHD (onset during the developmental period, typically early to mid-\nchildhood), AND\n(ii) documentation in the patient's medical records that an in-depth clinical interview with, or, obtainment of evidence from,\neither a:(a) parent, (b) teacher, (c) sibling, (d) third party, has occurred and which supports point (i) above.\nmethylphenidate hydrochloride 40 mg modified release capsule, 30\n2283E Max.Qty Packs No. of Rpts Premium $ DPMQ $ MRVSN $ Brand Name and Manufacturer Brand Name and Manufacturer\nN\n1 5 0.00 55.59 25.00 a ATTORA LA [XT] a Ritalin LA [NV]\na Rubifen LA [AE]\nmethylphenidate hydrochloride 40 mg modified release capsule, 30\n15100R Max.Qty Packs No. of Rpts Premium $ DPMQ $ MRVSN $ Brand Name and Manufacturer\nN\n1 5 0.00 268.41 25.\n  Source: `pbs/2026.pdf (http://www.pbs.gov.au/publication/schedule/2026/05/2026-05-01-general-soc.pdf)`\n- Authority\nPBS 1800 888 333\nRPBS 1800 552 580\nDepartment of Health, Disability and Ageing\nPh: 1800 020 613\nEmail\n: pbs@health.gov.au\nServices Australia\n(administers the PBS)\nGeneral enquiries 132 290\nDept of Veterans’ Affairs\nRPBS enquiries\nPh: 1800 552 580\nPoisons Information Centres\nPh 131 126 (24hrs)\nConsumer Medicines Information\nand adverse event reporting\n1300 MEDICINE\n(for consumers only)\nPh: 1300 633 424\nwww.1300medicine.com.au\nTherapeutic Goods Administration\nReport adverse drug reactions\nConsumer level recalls only\nPh: 1800 020 512\nTelephone Interpreter Service\nPh: 131 450 (24hrs)\nPBS Contacts\nContacts for Consumers\nContacts for Health Professionals\nContacts for Industry\nPBS Information Line\nFor further information on fees, patient contributions, benefit items and safety net\nthresholds — Free call 1800 020 613\nEnquiries from the media\n  Source: `pages/contact.html (http://www.pbs.gov.au/info/contacts/pbs-contacts)`\n- [pages 42,43]\nt must be assessed for the risks/benefits of a step-down in dosing from a high dose PPI administered twice daily,\nwith the determination being that the risks outweigh the benefits; treatment is for: (2) maintenance treatment; OR\n• Patient must have trialled a step-down in dosing, yet symptoms have re-emerged/worsened; treatment is for: (3) re-\nestablishment of symptom control; OR\n• Patient must have trialled a step-down in dosing, with symptoms adequately managed with once daily dosing; treatment\nis for: (2) maintenance treatment, but with the quantity sought in this authority application being up to 1 pack per\ndispensing.\n  Source: `other-pdfs/2026-05-01-general-schedule-Volume-1.pdf (http://www.pbs.gov.au/publication/schedule/2026/05/2026-05-01-general-schedule-Volume-1.pdf)`\n- [pages 65,66]\nLINED)\n4211\nNausea and vomiting\nClinical criteria:\n• The condition must be associated with cytotoxic chemotherapy being used to treat malignancy, AND\n• The treatment must be in combination with a 5-hydroxytryptamine receptor (5HT3) antagonist and dexamethasone, AND\n• Patient must be scheduled to be administered a chemotherapy regimen that includes any 1 of the following agents:\naltretamine; carmustine; cisplatin when a single dose constitutes a cycle of chemotherapy; cyclophosphamide at a dose\nof 1500 mg per square metre per day or greater; dacarbazine; procarbazine when a single dose constitutes a cycle of\nchemotherapy; streptozocin.\n  Source: `other-pdfs/2026-05-01-general-schedule-Volume-1.pdf (http://www.pbs.gov.au/publication/schedule/2026/05/2026-05-01-general-schedule-Volume-1.pdf)`\n- Authority required (STREAMLINED)\n6444\nNausea and vomiting\nClinical criteria:\n• The condition must be associated with moderately emetogenic cytotoxic chemotherapy being used to treat malignancy,\nAND\n• The treatment must be in combination with a 5-hydroxytryptamine receptor (5HT3) antagonist and dexamethasone on\nday 1 of a chemotherapy cycle, AND\n• Patient must have had a prior episode of chemotherapy induced nausea or vomiting, AND\n• Patient must be scheduled to be administered a chemotherapy regimen that includes any 1 of the following intravenous\nchemotherapy agents: arsenic trioxide; azacitidine; cyclophosphamide at a dose of less than 1500 mg per square metre\nper day; cytarabine at a dose of greater than 1 g per square metre per day; dactinomycin; daunorubicin; doxorubicin;\nepirubicin; fotemustine; idarubicin; ifosfamide; irinotecan; melphalan;\n  Source: `other-pdfs/2026-05-01-general-schedule-Volume-1.pdf (http://www.pbs.gov.au/publication/schedule/2026/05/2026-05-01-general-schedule-Volume-1.pdf)`\n- [Page 67]\nALIMENTARY TRACT AND METABOLISM\nGeneral Pharmaceutical Benefits 63\nlareneG\n• Patient must have had a prior episode of chemotherapy induced nausea or vomiting, AND\n• Patient must be scheduled to be administered a chemotherapy regimen that includes any 1 of the following intravenous\nchemotherapy agents: arsenic trioxide; azacitidine; cyclophosphamide at a dose of less than 1500 mg per square metre\nper day; cytarabine at a dose of greater than 1 g per square metre per day; dactinomycin; daunorubicin; doxorubicin;\nepirubicin; fotemustine; idarubicin; ifosfamide; irinotecan; melphalan; methotrexate at a dose of 250 mg to 1 g per square\nmetre; raltitrexed.\n  Source: `other-pdfs/2026-05-01-general-schedule-Volume-1.pdf (http://www.pbs.gov.au/publication/schedule/2026/05/2026-05-01-general-schedule-Volume-1.pdf)`\n\n### Strategic Priorities\n\n- If restriction is lengthy\nnew listing/change to listing) it may be paraphrased.)\nRAXTOZINAMERAN\nI.M. injection, suspension for injection containing\nraxtozinameran 30 micrograms\nNew vaccine - Prevention of\nTo request a National Immunisation Program listing for the\nprevention of coronavirus disease 2019 (COVID-19) caused by the\nComirnaty® Omicron XBB.1.5 coronavirus disease 2019 (COVID-19)\nSARS-CoV-2 virus in adults aged ≥ 18 years at increased risk of\ncaused by SARS-CoV-2\nsevere COVID-19 disease.\n  Source: `pbs/2025.pdf (http://www.pbs.gov.au/industry/listing/elements/pbac-meetings/agenda/pdf/2025/PBAC-Intracycle-meeting-agenda-DECEMBER-2025.pdf)`\n- Dose modification (where dose escalation occurs during initial treatment)\nIf an adequate clinical response has not been achieved after at least 1 month and up to 3 months of initial treatment, the\ndose may be increased to 120 micrograms/kg/day (maximum of 7,200 micrograms per day) through the dose modification\ntreatment phase for up to a total period of 6 months from the date of treatment commencement with odevixibat.\n  Source: `other-pdfs/2026-05-01-general-schedule-Volume-1.pdf (http://www.pbs.gov.au/publication/schedule/2026/05/2026-05-01-general-schedule-Volume-1.pdf)`\n- Document and retain in the patient's medical records the qualifying baseline laboratory reading for the purpose of assessing\nresponse to treatment under the 'Continuing treatment' restriction.\nobeticholic acid 5 mg tablet, 30\n12623J Max.Qty Packs No. of Rpts Premium $ DPMQ $ MRVSN $ Brand Name and Manufacturer\n1 5 ..\n  Source: `other-pdfs/2026-05-01-general-schedule-Volume-1.pdf (http://www.pbs.gov.au/publication/schedule/2026/05/2026-05-01-general-schedule-Volume-1.pdf)`\n- [pages 28,29]\ns)\nAlternatively, applications for authority to prescribe can be submitted online using the form upload facility in Health\nProfessional Online Services (HPOS) at www.servicesaustralia.gov.au/hpos\nOr mailed to:\nServices Australia\nComplex Drugs\nReply Paid 9826\nHOBART TAS 7001\nAuthority required\nSevere aplastic anaemia\nTreatment Phase: Initial treatment - Second line treatment\nClinical criteria:\n• The condition must be severe aplastic anaemia, AND\n• Patient must not have achieved an adequate response to prior immunosuppressive therapy including anti-thymocyte\nantibody and ciclosporin; OR\n• Patient must have relapsed following prior immunosuppressive therapy including anti-thymocyte antibody and ciclosporin,\nAND\n• Patient must not receive more than 16 weeks of treatment under this restriction.\n  Source: `other-pdfs/2026-05-01-general-schedule-Volume-2.pdf (http://www.pbs.gov.au/publication/schedule/2026/05/2026-05-01-general-schedule-Volume-2.pdf)`\n- [pages 1,2,3,4,5]\n[Page 1]\nOFFICIAL\nPHARMACEUTICAL BENEFITS ADVISORY COMMITTEE (PBAC) INTRACYCLE MEETING AGENDA\nDECEMBER 2025 PBAC INTRACYCLE MEETING\nPlease note that items in this agenda are subject to change at short notice.\n  Source: `pbs/2025.pdf (http://www.pbs.gov.au/industry/listing/elements/pbac-meetings/agenda/pdf/2025/PBAC-Intracycle-meeting-agenda-DECEMBER-2025.pdf)`\n- [pages 1,2,3,4]\n[Page 1]\nSchedule of\nPharmaceutical\nBenefits\nSummary of Changes\nEffective 1 May 2026\n  Source: `pbs/2026.pdf (http://www.pbs.gov.au/publication/schedule/2026/05/2026-05-01-general-soc.pdf)`\n- [Page 2]\nFees, Patient Contributions and\nSafety Net Thresholds\nThe following fees, patient contributions and safety net thresholds apply as at 1 May 2026 and are included, where applicable,\nin prices published in the Schedule —\nDispensing Fees: Ready-prepared $8.88\nDangerous drug fee $5.50\nExtemporaneously-prepared $10.92\nAllowable additional patient charge* $2.79\nAdditional Fees (for safety net prices): Ready-prepared $1.48\nExtemporaneously-prepared $1.91\nPatient Co-payments: General $25.00\nConcessional $7.70\nSafety Net Thresholds: General $1748.20\nConcessional $277.20\nSafety Net Card Issue Fee: $12.78\n* The allowable additional patient charge is a discretionary charge to general patients if a pharmaceutical item has a dispensed\nprice for maximum quantity less than the general patient co-payment.\n  Source: `pbs/2026.pdf (http://www.pbs.gov.au/publication/schedule/2026/05/2026-05-01-general-soc.pdf)`\n- [pages 4,5,6]\npressin acetate 10 microgram/actuation nasal spray, 50 actuations (Desmopressin\nNasal Spray USP (Apotex))\n15026W METHYLPHENIDATE, methylphenidate hydrochloride 10 mg modified release capsule, 30 (Methylphenidate\nOrifarm 10 mg (Sweden))\n15016H METHYLPHENIDATE, methylphenidate hydrochloride 20 mg modified release capsule, 30 (Methylphenidate\nOrifarm 20 mg (Sweden))\n15046X METHYLPHENIDATE, methylphenidate hydrochloride 30 mg modified release capsule, 30 (Methylphenidate\nOrifarm 30 mg (Sweden))\n15003P METHYLPHENIDATE, methylphenidate hydrochloride 60 mg modified release capsule, 30 (Methylphenidate\nOrifarm 60 mg (Denmark))\n14854T NAPROXEN, naproxen 125 mg/5 mL oral liquid, 474 mL (Pediapharm Naproxen Suspension 25 mg/mL\n(Medexus Pharma, Canada))\n4 Schedule of Pharmaceutical Benefits – May 2026\n  Source: `pbs/2026.pdf (http://www.pbs.gov.au/publication/schedule/2026/05/2026-05-01-general-soc.pdf)`\n- [pages 6,7,8]\nmg (Zentiva, UK), LM – CLOPIDOGREL, clopidogrel 75 mg tablet, 28\n14861E Concerta (Switzerland), DZ – METHYLPHENIDATE, methylphenidate hydrochloride 18 mg modified release\ntablet, 30\n14874W Concerta (Switzerland), DZ – METHYLPHENIDATE, methylphenidate hydrochloride 27 mg modified release\ntablet, 30\n15169J Atenza (Spain), XT – METHYLPHENIDATE, methylphenidate hydrochloride 27 mg modified release tablet, 30\n14858B Concerta (Switzerland), DZ – METHYLPHENIDATE, methylphenidate hydrochloride 36 mg modified release\ntablet, 30\n14853R Concerta (Switzerland), DZ – METHYLPHENIDATE, methylphenidate hydrochloride 54 mg modified release\ntablet, 30\n15198X Atenza (Spain), XT – METHYLPHENIDATE, methylphenidate hydrochloride 54 mg modified release tablet, 30\n6 Schedule of Pharmaceutical Benefits – May 2026\n  Source: `pbs/2026.pdf (http://www.pbs.gov.au/publication/schedule/2026/05/2026-05-01-general-soc.pdf)`\n- [pages 8,9]\nuent [2 mL syringe], 1 pack\n10549F Sandostatin LAR, NV – OCTREOTIDE, octreotide 20 mg modified release injection [1 vial] (&) inert substance\ndiluent [2 mL syringe], 1 pack\n10558Q Sandostatin LAR, NV – OCTREOTIDE, octreotide 30 mg modified release injection [1 vial] (&) inert substance\ndiluent [2 mL syringe], 1 pack\n11894B Sandostatin LAR, NV – OCTREOTIDE, octreotide 30 mg modified release injection [1 vial] (&) inert substance\ndiluent [2 mL syringe], 1 pack\nDeletion – Restriction\n14798W ESKETAMINE, esketamine 28 mg/2 actuations nasal spray, 3 x 2 actuations (Spravato)\n14811M ESKETAMINE, esketamine 28 mg/2 actuations nasal spray, 2 actuations (Spravato)\n14814Q ESKETAMINE, esketamine 28 mg/2 actuations nasal spray, 2 x 2 actuations (Spravato)\n8 Schedule of Pharmaceutical Benefits – May 2026\n  Source: `pbs/2026.pdf (http://www.pbs.gov.au/publication/schedule/2026/05/2026-05-01-general-soc.pdf)`\n\n## KPIs, Targets, and Where They Are At\n\n- Dose modification (where dose escalation occurs during initial treatment)\nIf an adequate clinical response has not been achieved after at least 1 month and up to 3 months of initial treatment, the\ndose may be increased to 120 micrograms/kg/day (maximum of 7,200 micrograms per day) through the dose modification\ntreatment phase for up to a total period of 6 months from the date of treatment commencement with odevixibat.\n  Source: `other-pdfs/2026-05-01-general-schedule-Volume-1.pdf (http://www.pbs.gov.au/publication/schedule/2026/05/2026-05-01-general-schedule-Volume-1.pdf)`\n- [pages 28,29]\ns)\nAlternatively, applications for authority to prescribe can be submitted online using the form upload facility in Health\nProfessional Online Services (HPOS) at www.servicesaustralia.gov.au/hpos\nOr mailed to:\nServices Australia\nComplex Drugs\nReply Paid 9826\nHOBART TAS 7001\nAuthority required\nSevere aplastic anaemia\nTreatment Phase: Initial treatment - Second line treatment\nClinical criteria:\n• The condition must be severe aplastic anaemia, AND\n• Patient must not have achieved an adequate response to prior immunosuppressive therapy including anti-thymocyte\nantibody and ciclosporin; OR\n• Patient must have relapsed following prior immunosuppressive therapy including anti-thymocyte antibody and ciclosporin,\nAND\n• Patient must not receive more than 16 weeks of treatment under this restriction.\n  Source: `other-pdfs/2026-05-01-general-schedule-Volume-2.pdf (http://www.pbs.gov.au/publication/schedule/2026/05/2026-05-01-general-schedule-Volume-2.pdf)`\n- If restriction is lengthy\nnew listing/change to listing) it may be paraphrased.)\nRAXTOZINAMERAN\nI.M. injection, suspension for injection containing\nraxtozinameran 30 micrograms\nNew vaccine - Prevention of\nTo request a National Immunisation Program listing for the\nprevention of coronavirus disease 2019 (COVID-19) caused by the\nComirnaty® Omicron XBB.1.5 coronavirus disease 2019 (COVID-19)\nSARS-CoV-2 virus in adults aged ≥ 18 years at increased risk of\ncaused by SARS-CoV-2\nsevere COVID-19 disease.\n  Source: `pbs/2025.pdf (http://www.pbs.gov.au/industry/listing/elements/pbac-meetings/agenda/pdf/2025/PBAC-Intracycle-meeting-agenda-DECEMBER-2025.pdf)`\n- Where applications (either on the same day or on separate days) for multiple strengths\nare sought with an intent to titrate patient's dosage, repeats should only be sought for the listed target strength\n18 Schedule of Pharmaceutical Benefits – May 2026\n  Source: `pbs/2026.pdf (http://www.pbs.gov.au/publication/schedule/2026/05/2026-05-01-general-soc.pdf)`\n- [pages 21,22]\nday or on separate days) for multiple strengths\nare sought with an intent to titrate patient's dosage, repeats should only be sought for the listed target strength\nNote A patient may only receive PBS-subsidised treatment with one form of long-acting methylphenidate at any one time.\n  Source: `pbs/2026.pdf (http://www.pbs.gov.au/publication/schedule/2026/05/2026-05-01-general-soc.pdf)`\n- Clinical criteria:\n• Patient must have achieved an adequate response to this drug, defined as having at least one of: (i) an alkaline\nphosphate (ALP) level less than 1.67 times the upper limit of normal (ULN), (ii) a reduction in the ALP reading of at least\n15% compared to the baseline level provided with the initial authority application, (iii) a total bilirubin level within the\nnormal reference range.\n  Source: `other-pdfs/2026-05-01-general-schedule-Volume-1.pdf (http://www.pbs.gov.au/publication/schedule/2026/05/2026-05-01-general-schedule-Volume-1.pdf)`\n- Document and retain in the patient's medical records the qualifying baseline laboratory reading for the purpose of assessing\nresponse to treatment under the 'Continuing treatment' restriction.\nobeticholic acid 5 mg tablet, 30\n12623J Max.Qty Packs No. of Rpts Premium $ DPMQ $ MRVSN $ Brand Name and Manufacturer\n1 5 ..\n  Source: `other-pdfs/2026-05-01-general-schedule-Volume-1.pdf (http://www.pbs.gov.au/publication/schedule/2026/05/2026-05-01-general-schedule-Volume-1.pdf)`\n- If an adequate clinical response has been achieved after 3 consecutive months since commencement of treatment,\nodevixibat should be renewed at 40 micrograms/kg/day through the continuing treatment phase.\n  Source: `other-pdfs/2026-05-01-general-schedule-Volume-1.pdf (http://www.pbs.gov.au/publication/schedule/2026/05/2026-05-01-general-schedule-Volume-1.pdf)`\n- Authority required\nEosinophilic oesophagitis\nTreatment Phase: Subsequent continuing treatment - Maintenance of remission\nClinical criteria:\n• Patient must have previously received PBS-subsidised treatment with this drug for this condition under the First\ncontinuing treatment restriction, AND\n• Patient must have documented evidence of having achieved histologic remission while receiving Initial and First\ncontinuing PBS-subsidised treatment with this drug for this condition, defined as a peak eosinophil count of less than 5\neosinophils per high power field (hpf), corresponding to less than 16 eosinophils per mm2 hpf on oesophageal biopsy,\nAND\n• The condition must not have progressed while being treated with this drug.\n  Source: `other-pdfs/2026-05-01-general-schedule-Volume-1.pdf (http://www.pbs.gov.au/publication/schedule/2026/05/2026-05-01-general-schedule-Volume-1.pdf)`\n- [pages 1,2,3,4,5]\n[Page 1]\nOFFICIAL\nPHARMACEUTICAL BENEFITS ADVISORY COMMITTEE (PBAC) INTRACYCLE MEETING AGENDA\nDECEMBER 2025 PBAC INTRACYCLE MEETING\nPlease note that items in this agenda are subject to change at short notice.\n  Source: `pbs/2025.pdf (http://www.pbs.gov.au/industry/listing/elements/pbac-meetings/agenda/pdf/2025/PBAC-Intracycle-meeting-agenda-DECEMBER-2025.pdf)`\n- [pages 1,2,3,4]\n[Page 1]\nSchedule of\nPharmaceutical\nBenefits\nSummary of Changes\nEffective 1 May 2026\n  Source: `pbs/2026.pdf (http://www.pbs.gov.au/publication/schedule/2026/05/2026-05-01-general-soc.pdf)`\n- [Page 2]\nFees, Patient Contributions and\nSafety Net Thresholds\nThe following fees, patient contributions and safety net thresholds apply as at 1 May 2026 and are included, where applicable,\nin prices published in the Schedule —\nDispensing Fees: Ready-prepared $8.88\nDangerous drug fee $5.50\nExtemporaneously-prepared $10.92\nAllowable additional patient charge* $2.79\nAdditional Fees (for safety net prices): Ready-prepared $1.48\nExtemporaneously-prepared $1.91\nPatient Co-payments: General $25.00\nConcessional $7.70\nSafety Net Thresholds: General $1748.20\nConcessional $277.20\nSafety Net Card Issue Fee: $12.78\n* The allowable additional patient charge is a discretionary charge to general patients if a pharmaceutical item has a dispensed\nprice for maximum quantity less than the general patient co-payment.\n  Source: `pbs/2026.pdf (http://www.pbs.gov.au/publication/schedule/2026/05/2026-05-01-general-soc.pdf)`\n- [pages 4,5,6]\npressin acetate 10 microgram/actuation nasal spray, 50 actuations (Desmopressin\nNasal Spray USP (Apotex))\n15026W METHYLPHENIDATE, methylphenidate hydrochloride 10 mg modified release capsule, 30 (Methylphenidate\nOrifarm 10 mg (Sweden))\n15016H METHYLPHENIDATE, methylphenidate hydrochloride 20 mg modified release capsule, 30 (Methylphenidate\nOrifarm 20 mg (Sweden))\n15046X METHYLPHENIDATE, methylphenidate hydrochloride 30 mg modified release capsule, 30 (Methylphenidate\nOrifarm 30 mg (Sweden))\n15003P METHYLPHENIDATE, methylphenidate hydrochloride 60 mg modified release capsule, 30 (Methylphenidate\nOrifarm 60 mg (Denmark))\n14854T NAPROXEN, naproxen 125 mg/5 mL oral liquid, 474 mL (Pediapharm Naproxen Suspension 25 mg/mL\n(Medexus Pharma, Canada))\n4 Schedule of Pharmaceutical Benefits – May 2026\n  Source: `pbs/2026.pdf (http://www.pbs.gov.au/publication/schedule/2026/05/2026-05-01-general-soc.pdf)`\n- [pages 6,7,8]\nmg (Zentiva, UK), LM – CLOPIDOGREL, clopidogrel 75 mg tablet, 28\n14861E Concerta (Switzerland), DZ – METHYLPHENIDATE, methylphenidate hydrochloride 18 mg modified release\ntablet, 30\n14874W Concerta (Switzerland), DZ – METHYLPHENIDATE, methylphenidate hydrochloride 27 mg modified release\ntablet, 30\n15169J Atenza (Spain), XT – METHYLPHENIDATE, methylphenidate hydrochloride 27 mg modified release tablet, 30\n14858B Concerta (Switzerland), DZ – METHYLPHENIDATE, methylphenidate hydrochloride 36 mg modified release\ntablet, 30\n14853R Concerta (Switzerland), DZ – METHYLPHENIDATE, methylphenidate hydrochloride 54 mg modified release\ntablet, 30\n15198X Atenza (Spain), XT – METHYLPHENIDATE, methylphenidate hydrochloride 54 mg modified release tablet, 30\n6 Schedule of Pharmaceutical Benefits – May 2026\n  Source: `pbs/2026.pdf (http://www.pbs.gov.au/publication/schedule/2026/05/2026-05-01-general-soc.pdf)`\n\n## Key Metrics\n\n| Values found | Evidence | Source |\n|---|---|---|\n| $8.88\n, $5.50\n, $10.92\n, $2.79\n, $1.48\n, $1.91 | [Page 2]\nFees, Patient Contributions and\nSafety Net Thresholds\nThe following fees, patient contributions and safety net thresholds apply as at 1 May 2026 and are included, where applicable,\nin prices published in the Schedule —\nDispensing Fees: Ready-prepared $8.88\nDangerous drug fee $5.50\nExtemporaneously-prepared $10.92\nAllowable additional patient charge* $2.79\nAdditional Fees (for safety net prices): Ready-prepared $1.48\nExtemporaneously-prep | `pbs/2026.pdf (http://www.pbs.gov.au/publication/schedule/2026/05/2026-05-01-general-soc.pdf)` |\n| $25.00 , $7.70 | Following a reduction in the general co-payment amount, from 1 January 2026, you may\npay up to $25.00 for most PBS medicines, or $7.70 if you have a concession card. | `pages/about.html (http://www.pbs.gov.au/info/about-the-pbs)` |\n| $0.60, $0.80 , $7.70, $0.20 | From 1 January 2026, the allowable co-payment discount for concessional patients\nwill be $0.60, as the allowable $0.80 discount will decrease by the amount of indexation\n(in dollars) that would have normally applied to the concessional co-payment of $7.70,\ni.e., $0.20. | `pages/about.html (http://www.pbs.gov.au/info/about-the-pbs)` |\n| $277.20 , $1,748.20 | Safety Net\nFrom 1 January 2026, the PBS Safety Net threshold for patients with a concession card\nwill remain at $277.20 and for other eligible patients it will be $1,748.20. | `pages/about.html (http://www.pbs.gov.au/info/about-the-pbs)` |\n| $3, $4 | \b\n\u000b\u000b\u000b\u000f\u000e\n\u0010\u0014!\u0015\u0014\u0012\u0012\u0014(\u001d\u001e\u0018!0*21/*.-4;K@48G9-.BYBGNPTUT3?]c\\RbKSTQ��C\u0001\u000e\u000f\u000f\u0014\u0011\u0014'\u0015\u0015'Q6.6QQQQQQQQQQQQQQQQQQQQQQQQQQQQQQQQQQQQQQQQQQQQQQQQQQ��\u0011\bJ\u0004�\u0003\u0001\"\u0002\u0011\u0001\u0003\u0011\u0001��\u001f\u0001\u0005\u0001\u0001\u0001\u0001\u0001\u0001\u0001\u0002\u0003\u0004\u0005\u0006\u0007\b \n\u000b���\u0010\u0002\u0001\u0003\u0003\u0002\u0004\u0003\u0005\u0005\u0004\u0004\u0001}\u0001\u0002\u0003\u0004\u0011\u0005\u0012!1A\u0006\u0013Qa\u0007\"q\u00142���\b#B��\u0015R��$3br� \n\u0016\u0017\u0018\u0019\u001a%&'()*456789:CDEFGHIJSTUVWXYZcdefghijstuvwxyz���������������������������������������������������������������������������\u001f\u0001\u0003\u0001\u0001\u0001\u0001\u0001\u0001\u0001\u0001\u0001\u0001\u0002\u0003\u0004\u0005\u0006\u0007\b \n\u000b���\u0011\u0002\u0001\u0002\u0004\u0004\u0003\u0004\u0007\u0005\u0004\u0004\u0001\u0002w\u0001\u0002\u0003\u0011\u0004\u0005!1\u0006\u0012AQ\u0007aq\u0013\"2�\b\u0014B���� #3R�\u0015br�\n\u0016$4�%�\u0017\u0018\u0019\u001a&'()*56789:CDEFGHI | `pages/announcements-index.html (http://www.pbs.gov.au/files/pbac-membership/Statement-of-Expectations-for-the-PBAC-Chair-Professor-Robyn-Ward-2024.pdf)` |\n| $8.88\n, $5.50\n, $10.92\n, $2.79\n, $1.48\n, $1.91 | [Page 5]\nFees, Patient Contributions and\nSafety Net Thresholds\nThe following fees, patient contributions and safety net thresholds apply as at 1 May 2026 and are included, where applicable,\nin prices published in the Schedule —\nDispensing Fees: Ready-prepared $8.88\nDangerous drug fee $5.50\nExtemporaneously-prepared $10.92\nAllowable additional patient charge* $2.79\nAdditional Fees (for safety net prices): Ready-prepared $1.48\nExtemporaneously-prep | `other-pdfs/2026-05-01-general-schedule-Volume-1.pdf (http://www.pbs.gov.au/publication/schedule/2026/05/2026-05-01-general-schedule-Volume-1.pdf)` |\n| $8.88\n, $5.50\n, $10.92\n, $2.79\n, $1.48\n, $1.91 | [pages 5,6,7]\ndy-prepared $8.88\nDangerous drug fee $5.50\nExtemporaneously-prepared $10.92\nAllowable additional patient charge* $2.79\nAdditional Fees (for safety net prices): Ready-prepared $1.48\nExtemporaneously-prepared $1.91\nPatient Co-payments: General $25.00\nConcessional $7.70\nSafety Net Thresholds: General $1748.20\nConcessional $277.20\nSafety Net Card Issue Fee: $12.78\n* The allowable additional patient charge is a discretionary charge to ge | `other-pdfs/2026-05-01-general-schedule-Volume-1.pdf (http://www.pbs.gov.au/publication/schedule/2026/05/2026-05-01-general-schedule-Volume-1.pdf)` |\n| 1.2 million | [Page 24]\n20 Schedule of Pharmaceutical Benefits – May 2026\nPrescriber\nBag\n ADRENALINE (EPINEPHRINE)\nadrenaline (epinephrine) 1 in 1000 (1 mg/mL) injection, 5 x 1 mL ampoules\n3451P Max.Qty Packs DPMQ $ Brand Name and Manufacturer\nNP M W\n1 21.43 Link Medical Products Pty Ltd [LM]\n ATROPINE SULFATE\natropine sulfate monohydrate 600 microgram/mL injection, 10 x 1 mL ampoules\n3453R Max.Qty Packs DPMQ $ Brand Name and Manufacturer\nNP\n1 29.78 Atropine | `other-pdfs/2026-05-01-general-schedule-Volume-1.pdf (http://www.pbs.gov.au/publication/schedule/2026/05/2026-05-01-general-schedule-Volume-1.pdf)` |\n| 20,000 million, 30,000 million | The following criteria indicate failure to achieve an adequate response to corticosteroid and/or immunoglobulin therapy and\nmust be demonstrated at the time of initial application;\n(a) a platelet count of less than or equal to 20,000 million per L; OR\n(b) a platelet count of 20,000 million to 30,000 million per L, where the patient is experiencing significant bleeding or has a\nhistory of significant bleeding in this platelet range. | `other-pdfs/2026-05-01-general-schedule-Volume-2.pdf (http://www.pbs.gov.au/publication/schedule/2026/05/2026-05-01-general-schedule-Volume-2.pdf)` |\n| $0.60\n, $7.70 | Concessional patients will be eligible for a discount of up to $0.60\noff the concessional patient co-payment of $7.70 in 2026. | `pages/about.html (http://www.pbs.gov.au/info/about-the-pbs)` |\n| $7.70 | The concessional patient co-payment will not be indexed on 1 January 2026 and remain\nat the amount of $7.70 until 2029. | `pages/about.html (http://www.pbs.gov.au/info/about-the-pbs)` |\n| $8.88\n, $5.50\n, $10.92\n, $2.79\n, $1.48\n, $1.91 | [Page 2]\nFees, Patient Contributions and\nSafety Net Thresholds\nThe following fees, patient contributions and safety net thresholds apply as at 1 May 2026 and are included, where applicable,\nin prices published in the Schedule —\nDispensing Fees: Ready-prepared $8.88\nDangerous drug fee $5.50\nExtemporaneously-prepared $10.92\nAllowable additional patient charge* $2.79\nAdditional Fees (for safety net prices): Ready-prepared $1.48\nExtemporaneously-prep | `pbs/2026.pdf (http://www.pbs.gov.au/publication/schedule/2026/05/2026-05-01-general-soc.pdf)` |\n\n## Key Achievements\n\n- The authority application must be made in writing and must include:\n(a) details of the proposed prescription(s); and\n(b) a completed authority application form relevant to the indication and treatment phase (the latest version is located on the\nwebsite specified in the Administrative Advice).\nteduglutide 5 mg injection [28 vials] (&) inert substance diluent [28 x 0.5 mL syringes], 1 pack\n11806J Max.Qty Packs No. of Rpts Premium $ DPMQ $ Brand Name and Manufacturer\n1 5 ..\n  Source: `other-pdfs/2026-05-01-general-schedule-Volume-2.pdf (http://www.pbs.gov.au/publication/schedule/2026/05/2026-05-01-general-schedule-Volume-2.pdf)`\n- [Page 42]\nCARDIOVASCULAR SYSTEM\n38 Schedule of Pharmaceutical Benefits – May 2026\nHSD\n(Private)\nIf the application is submitted through HPOS form upload or mail, it must include:\n(a) details of the proposed prescription; and\n(b) a completed authority application form relevant to the indication and treatment phase (the latest version is located on the\nwebsite specified in the Administrative Advice).\n(1) Confirm that the patient has a diagnosis of pulmonary arterial hypertension (PAH) in line with the following definition:\n(a) mean pulmonary artery pressure (mPAP) at least 25 mmHg at rest and pulmonary artery wedge pressure (PAWP) no\ngreater than 15 mmHg; or\n(b) where right heart catheterisation (RHC) cannot be performed on clinical grounds, right ventricular systolic pressure\nassessed by echocardiography (ECHO) is greater than 40 mmHg, with normal left ventricular function.\n  Source: `other-pdfs/2026-05-01-general-schedule-Volume-2.pdf (http://www.pbs.gov.au/publication/schedule/2026/05/2026-05-01-general-schedule-Volume-2.pdf)`\n- [pages 45,46]\nrescription; and\n(b) a completed authority application form relevant to the indication and treatment phase (the latest version is located on the\nwebsite specified in the Administrative Advice).\n(1) Confirm that the patient has a diagnosis of pulmonary arterial hypertension (PAH) in line with the following definition:\n(a) mean pulmonary artery pressure (mPAP) at least 25 mmHg at rest and pulmonary artery wedge pressure (PAWP) no\ngreater than 15 mmHg; or\n(b) where right heart catheterisation (RHC) cannot be performed on clinical grounds, right ventricular systolic pressure\nassessed by echocardiography (ECHO) is greater than 40 mmHg, with normal left ventricular function.\n(2) Confirm that in forming the diagnosis of PAH, the following tests have been conducted:\n- RHC composite assessment; and\n  Source: `other-pdfs/2026-05-01-general-schedule-Volume-2.pdf (http://www.pbs.gov.au/publication/schedule/2026/05/2026-05-01-general-schedule-Volume-2.pdf)`\n- [Page 62]\nCARDIOVASCULAR SYSTEM\n58 Schedule of Pharmaceutical Benefits – May 2026\nHSD\n(Private)\n(a) details of the proposed prescription; and\n(b) a completed authority application form relevant to the indication and treatment phase (the latest version is located on the\nwebsite specified in the Administrative Advice).\n(1) Confirm that the patient has a diagnosis of pulmonary arterial hypertension (PAH) in line with the following definition:\n(a) mean pulmonary artery pressure (mPAP) at least 25 mmHg at rest and pulmonary artery wedge pressure (PAWP) no\ngreater than 15 mmHg; or\n(b) where right heart catheterisation (RHC) cannot be performed on clinical grounds, right ventricular systolic pressure\nassessed by echocardiography (ECHO) is greater than 40 mmHg, with normal left ventricular function.\n(2) Confirm that in forming the diagnosis of PAH, the following tests have been conducted:\n  Source: `other-pdfs/2026-05-01-general-schedule-Volume-2.pdf (http://www.pbs.gov.au/publication/schedule/2026/05/2026-05-01-general-schedule-Volume-2.pdf)`\n- [Page 64]\nCARDIOVASCULAR SYSTEM\n60 Schedule of Pharmaceutical Benefits – May 2026\nHSD\n(Private)\n(b) a completed authority application form relevant to the indication and treatment phase (the latest version is located on the\nwebsite specified in the Administrative Advice).\n(1) Confirm that the patient has a diagnosis of pulmonary arterial hypertension (PAH) in line with the following definition:\n(a) mean pulmonary artery pressure (mPAP) at least 25 mmHg at rest and pulmonary artery wedge pressure (PAWP) no\ngreater than 15 mmHg; or\n(b) where right heart catheterisation (RHC) cannot be performed on clinical grounds, right ventricular systolic pressure\nassessed by echocardiography (ECHO) is greater than 40 mmHg, with normal left ventricular function.\n(2) Confirm that in forming the diagnosis of PAH, the following tests have been conducted:\n- RHC composite assessment; and\n  Source: `other-pdfs/2026-05-01-general-schedule-Volume-2.pdf (http://www.pbs.gov.au/publication/schedule/2026/05/2026-05-01-general-schedule-Volume-2.pdf)`\n- [pages 69,70]\ne:\n(a) details of the proposed prescription; and\n(b) a completed authority application form relevant to the indication and treatment phase (the latest version is located on the\nwebsite specified in the Administrative Advice).\n(1) Confirm that the patient has a diagnosis of pulmonary arterial hypertension (PAH) in line with the following definition:\n(a) mean pulmonary artery pressure (mPAP) at least 25 mmHg at rest and pulmonary artery wedge pressure (PAWP) no\ngreater than 15 mmHg; or\n(b) where right heart catheterisation (RHC) cannot be performed on clinical grounds, right ventricular systolic pressure\nassessed by echocardiography (ECHO) is greater than 40 mmHg, with normal left ventricular function.\n(2) Confirm that in forming the diagnosis of PAH, the following tests have been conducted:\n  Source: `other-pdfs/2026-05-01-general-schedule-Volume-2.pdf (http://www.pbs.gov.au/publication/schedule/2026/05/2026-05-01-general-schedule-Volume-2.pdf)`\n- If restriction is lengthy\nnew listing/change to listing) it may be paraphrased.)\nRAXTOZINAMERAN\nI.M. injection, suspension for injection containing\nraxtozinameran 30 micrograms\nNew vaccine - Prevention of\nTo request a National Immunisation Program listing for the\nprevention of coronavirus disease 2019 (COVID-19) caused by the\nComirnaty® Omicron XBB.1.5 coronavirus disease 2019 (COVID-19)\nSARS-CoV-2 virus in adults aged ≥ 18 years at increased risk of\ncaused by SARS-CoV-2\nsevere COVID-19 disease.\n  Source: `pbs/2025.pdf (http://www.pbs.gov.au/industry/listing/elements/pbac-meetings/agenda/pdf/2025/PBAC-Intracycle-meeting-agenda-DECEMBER-2025.pdf)`\n- Dose modification (where dose escalation occurs during initial treatment)\nIf an adequate clinical response has not been achieved after at least 1 month and up to 3 months of initial treatment, the\ndose may be increased to 120 micrograms/kg/day (maximum of 7,200 micrograms per day) through the dose modification\ntreatment phase for up to a total period of 6 months from the date of treatment commencement with odevixibat.\n  Source: `other-pdfs/2026-05-01-general-schedule-Volume-1.pdf (http://www.pbs.gov.au/publication/schedule/2026/05/2026-05-01-general-schedule-Volume-1.pdf)`\n- Document and retain in the patient's medical records the qualifying baseline laboratory reading for the purpose of assessing\nresponse to treatment under the 'Continuing treatment' restriction.\nobeticholic acid 5 mg tablet, 30\n12623J Max.Qty Packs No. of Rpts Premium $ DPMQ $ MRVSN $ Brand Name and Manufacturer\n1 5 ..\n  Source: `other-pdfs/2026-05-01-general-schedule-Volume-1.pdf (http://www.pbs.gov.au/publication/schedule/2026/05/2026-05-01-general-schedule-Volume-1.pdf)`\n- [pages 28,29]\ns)\nAlternatively, applications for authority to prescribe can be submitted online using the form upload facility in Health\nProfessional Online Services (HPOS) at www.servicesaustralia.gov.au/hpos\nOr mailed to:\nServices Australia\nComplex Drugs\nReply Paid 9826\nHOBART TAS 7001\nAuthority required\nSevere aplastic anaemia\nTreatment Phase: Initial treatment - Second line treatment\nClinical criteria:\n• The condition must be severe aplastic anaemia, AND\n• Patient must not have achieved an adequate response to prior immunosuppressive therapy including anti-thymocyte\nantibody and ciclosporin; OR\n• Patient must have relapsed following prior immunosuppressive therapy including anti-thymocyte antibody and ciclosporin,\nAND\n• Patient must not receive more than 16 weeks of treatment under this restriction.\n  Source: `other-pdfs/2026-05-01-general-schedule-Volume-2.pdf (http://www.pbs.gov.au/publication/schedule/2026/05/2026-05-01-general-schedule-Volume-2.pdf)`\n- Authority required\nPulmonary arterial hypertension (PAH)\nTreatment Phase: Initial treatment following dose titration\nClinical criteria:\n• Patient must have WHO Functional Class III PAH at treatment initiation with this drug; OR\n• Patient must have WHO Functional Class IV PAH at treatment initiation with this drug, AND\n• The treatment must form part of triple combination therapy consisting of: (i) one endothelin receptor antagonist, (ii) one\nphosphodiesterase-5 inhibitor, (iii) selexipag (referred to as 'triple therapy'); OR\n• The treatment must form part of dual combination therapy consisting of either: (i) selexipag with one endothelin receptor\nantagonist, (ii) selexipag with one phosphodiesterase-5 inhibitor, as triple combination therapy with selexipag-an\nendothelin receptor antagonist-a phoshodiesterase-5 inhibitor is not possible due to an intolerance/contraindication to the\n  Source: `other-pdfs/2026-05-01-general-schedule-Volume-2.pdf (http://www.pbs.gov.au/publication/schedule/2026/05/2026-05-01-general-schedule-Volume-2.pdf)`\n- [pages 1,2,3,4,5]\n[Page 1]\nOFFICIAL\nPHARMACEUTICAL BENEFITS ADVISORY COMMITTEE (PBAC) INTRACYCLE MEETING AGENDA\nDECEMBER 2025 PBAC INTRACYCLE MEETING\nPlease note that items in this agenda are subject to change at short notice.\n  Source: `pbs/2025.pdf (http://www.pbs.gov.au/industry/listing/elements/pbac-meetings/agenda/pdf/2025/PBAC-Intracycle-meeting-agenda-DECEMBER-2025.pdf)`\n\n## Key Issues, Risks, and Recommendations\n\n- If restriction is lengthy\nnew listing/change to listing) it may be paraphrased.)\nRAXTOZINAMERAN\nI.M. injection, suspension for injection containing\nraxtozinameran 30 micrograms\nNew vaccine - Prevention of\nTo request a National Immunisation Program listing for the\nprevention of coronavirus disease 2019 (COVID-19) caused by the\nComirnaty® Omicron XBB.1.5 coronavirus disease 2019 (COVID-19)\nSARS-CoV-2 virus in adults aged ≥ 18 years at increased risk of\ncaused by SARS-CoV-2\nsevere COVID-19 disease.\n  Source: `pbs/2025.pdf (http://www.pbs.gov.au/industry/listing/elements/pbac-meetings/agenda/pdf/2025/PBAC-Intracycle-meeting-agenda-DECEMBER-2025.pdf)`\n- [Page 2]\nFees, Patient Contributions and\nSafety Net Thresholds\nThe following fees, patient contributions and safety net thresholds apply as at 1 May 2026 and are included, where applicable,\nin prices published in the Schedule —\nDispensing Fees: Ready-prepared $8.88\nDangerous drug fee $5.50\nExtemporaneously-prepared $10.92\nAllowable additional patient charge* $2.79\nAdditional Fees (for safety net prices): Ready-prepared $1.48\nExtemporaneously-prepared $1.91\nPatient Co-payments: General $25.00\nConcessional $7.70\nSafety Net Thresholds: General $1748.20\nConcessional $277.20\nSafety Net Card Issue Fee: $12.78\n* The allowable additional patient charge is a discretionary charge to general patients if a pharmaceutical item has a dispensed\nprice for maximum quantity less than the general patient co-payment.\n  Source: `pbs/2026.pdf (http://www.pbs.gov.au/publication/schedule/2026/05/2026-05-01-general-soc.pdf)`\n- [Page 5]\nFees, Patient Contributions and\nSafety Net Thresholds\nThe following fees, patient contributions and safety net thresholds apply as at 1 May 2026 and are included, where applicable,\nin prices published in the Schedule —\nDispensing Fees: Ready-prepared $8.88\nDangerous drug fee $5.50\nExtemporaneously-prepared $10.92\nAllowable additional patient charge* $2.79\nAdditional Fees (for safety net prices): Ready-prepared $1.48\nExtemporaneously-prepared $1.91\nPatient Co-payments: General $25.00\nConcessional $7.70\nSafety Net Thresholds: General $1748.20\nConcessional $277.20\nSafety Net Card Issue Fee: $12.78\n* The allowable additional patient charge is a discretionary charge to general patients if a pharmaceutical item has a dispensed\nprice for maximum quantity less than the general patient co-payment.\n  Source: `other-pdfs/2026-05-01-general-schedule-Volume-1.pdf (http://www.pbs.gov.au/publication/schedule/2026/05/2026-05-01-general-schedule-Volume-1.pdf)`\n- [pages 5,6,7]\ndy-prepared $8.88\nDangerous drug fee $5.50\nExtemporaneously-prepared $10.92\nAllowable additional patient charge* $2.79\nAdditional Fees (for safety net prices): Ready-prepared $1.48\nExtemporaneously-prepared $1.91\nPatient Co-payments: General $25.00\nConcessional $7.70\nSafety Net Thresholds: General $1748.20\nConcessional $277.20\nSafety Net Card Issue Fee: $12.78\n* The allowable additional patient charge is a discretionary charge to general patients if a pharmaceutical item has a dispensed\nprice for maximum quantity less than the general patient co-payment.\n  Source: `other-pdfs/2026-05-01-general-schedule-Volume-1.pdf (http://www.pbs.gov.au/publication/schedule/2026/05/2026-05-01-general-schedule-Volume-1.pdf)`\n- [pages 42,43]\nt must be assessed for the risks/benefits of a step-down in dosing from a high dose PPI administered twice daily,\nwith the determination being that the risks outweigh the benefits; treatment is for: (2) maintenance treatment; OR\n• Patient must have trialled a step-down in dosing, yet symptoms have re-emerged/worsened; treatment is for: (3) re-\nestablishment of symptom control; OR\n• Patient must have trialled a step-down in dosing, with symptoms adequately managed with once daily dosing; treatment\nis for: (2) maintenance treatment, but with the quantity sought in this authority application being up to 1 pack per\ndispensing.\n  Source: `other-pdfs/2026-05-01-general-schedule-Volume-1.pdf (http://www.pbs.gov.au/publication/schedule/2026/05/2026-05-01-general-schedule-Volume-1.pdf)`\n- Clinical criteria:\n• The treatment must be: (i) the sole PBS-subsidised proton pump inhibitor (PPI) for this condition, (ii) the sole strength of\nthis PPI, (iii) the sole form of PPI, AND\n• Patient must must have symptoms inadequately controlled with each of: (i) a standard dose proton pump inhibitor (PPI)\nadministered once daily, (ii) a low dose PPI administered twice daily; treatment is for: (1) establishment of symptom\ncontrol; OR\n• Patient must be assessed for the risks/benefits of a step-down in dosing from standard dose PPI administered twice daily,\nwith the determination being that the risks outweigh the benefits; treatment is for: (2) maintenance treatment; OR\n• Patient must have trialled a step-down in dosing, yet symptoms have re-emerged/worsened; treatment is for: (3) re-\nestablishment of symptom control; OR\n  Source: `other-pdfs/2026-05-01-general-schedule-Volume-1.pdf (http://www.pbs.gov.au/publication/schedule/2026/05/2026-05-01-general-schedule-Volume-1.pdf)`\n- [pages 56,57]\nment must be: (i) the sole PBS-subsidised proton pump inhibitor (PPI) for this condition, (ii) the sole strength of\nthis PPI, (iii) the sole form of PPI, AND\n• Patient must must have symptoms inadequately controlled with each of: (i) a standard dose proton pump inhibitor (PPI)\nadministered once daily, (ii) a low dose PPI administered twice daily; treatment is for: (1) establishment of symptom\ncontrol; OR\n• Patient must be assessed for the risks/benefits of a step-down in dosing from standard dose PPI administered twice daily,\nwith the determination being that the risks outweigh the benefits; treatment is for: (2) maintenance treatment; OR\n• Patient must have trialled a step-down in dosing, yet symptoms have re-emerged/worsened; treatment is for: (3) re-\nestablishment of symptom control; OR\n  Source: `other-pdfs/2026-05-01-general-schedule-Volume-1.pdf (http://www.pbs.gov.au/publication/schedule/2026/05/2026-05-01-general-schedule-Volume-1.pdf)`\n- Dose modification (where dose escalation occurs during initial treatment)\nIf an adequate clinical response has not been achieved after at least 1 month and up to 3 months of initial treatment, the\ndose may be increased to 120 micrograms/kg/day (maximum of 7,200 micrograms per day) through the dose modification\ntreatment phase for up to a total period of 6 months from the date of treatment commencement with odevixibat.\n  Source: `other-pdfs/2026-05-01-general-schedule-Volume-1.pdf (http://www.pbs.gov.au/publication/schedule/2026/05/2026-05-01-general-schedule-Volume-1.pdf)`\n- Risk factors for developing stroke or systemic ischaemic embolism are:\n(i) Prior stroke (ischaemic or unknown type), transient ischaemic attack or non-central nervous system (CNS) systemic\nembolism;\n(ii) age 75 years or older;\n(iii) hypertension;\n(iv) diabetes mellitus;\n(v) heart failure and/or left ventricular ejection fraction 35% or less.\n  Source: `pbs/2026.pdf (http://www.pbs.gov.au/publication/schedule/2026/05/2026-05-01-general-soc.pdf)`\n- Document and retain in the patient's medical records the qualifying baseline laboratory reading for the purpose of assessing\nresponse to treatment under the 'Continuing treatment' restriction.\nobeticholic acid 5 mg tablet, 30\n12623J Max.Qty Packs No. of Rpts Premium $ DPMQ $ MRVSN $ Brand Name and Manufacturer\n1 5 ..\n  Source: `other-pdfs/2026-05-01-general-schedule-Volume-1.pdf (http://www.pbs.gov.au/publication/schedule/2026/05/2026-05-01-general-schedule-Volume-1.pdf)`\n- [pages 28,29]\ns)\nAlternatively, applications for authority to prescribe can be submitted online using the form upload facility in Health\nProfessional Online Services (HPOS) at www.servicesaustralia.gov.au/hpos\nOr mailed to:\nServices Australia\nComplex Drugs\nReply Paid 9826\nHOBART TAS 7001\nAuthority required\nSevere aplastic anaemia\nTreatment Phase: Initial treatment - Second line treatment\nClinical criteria:\n• The condition must be severe aplastic anaemia, AND\n• Patient must not have achieved an adequate response to prior immunosuppressive therapy including anti-thymocyte\nantibody and ciclosporin; OR\n• Patient must have relapsed following prior immunosuppressive therapy including anti-thymocyte antibody and ciclosporin,\nAND\n• Patient must not receive more than 16 weeks of treatment under this restriction.\n  Source: `other-pdfs/2026-05-01-general-schedule-Volume-2.pdf (http://www.pbs.gov.au/publication/schedule/2026/05/2026-05-01-general-schedule-Volume-2.pdf)`\n- If patients will be taking 62.5mg for longer than 1 month, prescribers should request the first authority prescription of therapy\nwith the 62.5 mg tablet strength, with the quantity for one month of treatment and a maximum of 5 repeats based on the\ndosage recommendations in the TGA-approved Product Information.\n  Source: `other-pdfs/2026-05-01-general-schedule-Volume-2.pdf (http://www.pbs.gov.au/publication/schedule/2026/05/2026-05-01-general-schedule-Volume-2.pdf)`\n- [pages 1,2,3,4,5]\n[Page 1]\nOFFICIAL\nPHARMACEUTICAL BENEFITS ADVISORY COMMITTEE (PBAC) INTRACYCLE MEETING AGENDA\nDECEMBER 2025 PBAC INTRACYCLE MEETING\nPlease note that items in this agenda are subject to change at short notice.\n  Source: `pbs/2025.pdf (http://www.pbs.gov.au/industry/listing/elements/pbac-meetings/agenda/pdf/2025/PBAC-Intracycle-meeting-agenda-DECEMBER-2025.pdf)`\n- [pages 1,2,3,4]\n[Page 1]\nSchedule of\nPharmaceutical\nBenefits\nSummary of Changes\nEffective 1 May 2026\n  Source: `pbs/2026.pdf (http://www.pbs.gov.au/publication/schedule/2026/05/2026-05-01-general-soc.pdf)`\n\n## Corporate Values and Operating Culture\n\n- [pages 28,29]\ns)\nAlternatively, applications for authority to prescribe can be submitted online using the form upload facility in Health\nProfessional Online Services (HPOS) at www.servicesaustralia.gov.au/hpos\nOr mailed to:\nServices Australia\nComplex Drugs\nReply Paid 9826\nHOBART TAS 7001\nAuthority required\nSevere aplastic anaemia\nTreatment Phase: Initial treatment - Second line treatment\nClinical criteria:\n• The condition must be severe aplastic anaemia, AND\n• Patient must not have achieved an adequate response to prior immunosuppressive therapy including anti-thymocyte\nantibody and ciclosporin; OR\n• Patient must have relapsed following prior immunosuppressive therapy including anti-thymocyte antibody and ciclosporin,\nAND\n• Patient must not receive more than 16 weeks of treatment under this restriction.\n  Source: `other-pdfs/2026-05-01-general-schedule-Volume-2.pdf (http://www.pbs.gov.au/publication/schedule/2026/05/2026-05-01-general-schedule-Volume-2.pdf)`\n- Authority Required (STREAMLINED)\n17117\nModerate to severe Crohn disease\nTreatment Phase: Subsequent continuing treatment\nClinical criteria:\n• Patient must have previously received PBS-subsidised treatment with this drug for this condition under the First\ncontinuing treatment restriction, AND\n• Patient must have both:\n(i) a total PCDAI score of 30 points or less, AND (ii) a reduction in PCDAI score by at least 15 points from baseline value;\nor\n• Patient must have an adequate response to this drug defined as an improvement of intestinal inflammation as\ndemonstrated by:\n(i) blood: normalisation of the platelet count, or an erythrocyte sedimentation rate (ESR) level no greater than 25 mm per\nhour, or a C-reactive protein (CRP) level no greater than 15 mg per L; or (ii) faeces: normalisation of lactoferrin or\ncalprotectin level;\n  Source: `pbs/2026.pdf (http://www.pbs.gov.au/publication/schedule/2026/05/2026-05-01-general-soc.pdf)`\n- [pages 26,27]\nPatient must have both:\n(i) a total PCDAI score of 30 points or less, AND (ii) a reduction in PCDAI score by at least 15 points from baseline value;\nor\n• Patient must have an adequate response to this drug defined as an improvement of intestinal inflammation as\ndemonstrated by:\n(i) blood: normalisation of the platelet count, or an erythrocyte sedimentation rate (ESR) level no greater than 25 mm per\nhour, or a C-reactive protein (CRP) level no greater than 15 mg per L; or (ii) faeces: normalisation of lactoferrin or\ncalprotectin level; or (iii) evidence of mucosal healing, as demonstrated by diagnostic imaging findings, compared to the\nbaseline assessment, AND\n• Patient must not receive more than 24 weeks of treatment under this restriction.\n  Source: `pbs/2026.pdf (http://www.pbs.gov.au/publication/schedule/2026/05/2026-05-01-general-soc.pdf)`\n- Authority Required (STREAMLINED)\n17120\nModerate to severe Crohn disease\nTreatment Phase: Subsequent continuing treatment\nClinical criteria:\n• Patient must have previously received PBS-subsidised treatment with this drug for this condition under the First\ncontinuing treatment restriction, AND\n• Patient must have both:\n(i) a total PCDAI score of 30 points or less, AND (ii) a reduction in PCDAI score by at least 15 points from baseline value;\nor\n• Patient must have an adequate response to this drug defined as an improvement of intestinal inflammation as\ndemonstrated by:\n(i) blood: normalisation of the platelet count, or an erythrocyte sedimentation rate (ESR) level no greater than 25 mm per\nhour, or a C-reactive protein (CRP) level no greater than 15 mg per L; or (ii) faeces: normalisation of lactoferrin or\ncalprotectin level;\n  Source: `pbs/2026.pdf (http://www.pbs.gov.au/publication/schedule/2026/05/2026-05-01-general-soc.pdf)`\n- [pages 32,33]\nPatient must have both:\n(i) a total PCDAI score of 30 points or less, AND (ii) a reduction in PCDAI score by at least 15 points from baseline value;\nor\n• Patient must have an adequate response to this drug defined as an improvement of intestinal inflammation as\ndemonstrated by:\n(i) blood: normalisation of the platelet count, or an erythrocyte sedimentation rate (ESR) level no greater than 25 mm per\nhour, or a C-reactive protein (CRP) level no greater than 15 mg per L; or (ii) faeces: normalisation of lactoferrin or\ncalprotectin level; or (iii) evidence of mucosal healing, as demonstrated by diagnostic imaging findings, compared to the\nbaseline assessment, AND\n• Patient must not receive more than 24 weeks of treatment under this restriction.\n  Source: `pbs/2026.pdf (http://www.pbs.gov.au/publication/schedule/2026/05/2026-05-01-general-soc.pdf)`\n- Authority\nPBS 1800 888 333\nRPBS 1800 552 580\nDepartment of Health, Disability and Ageing\nPh: 1800 020 613\nEmail\n: pbs@health.gov.au\nServices Australia\n(administers the PBS)\nGeneral enquiries 132 290\nDept of Veterans’ Affairs\nRPBS enquiries\nPh: 1800 552 580\nPoisons Information Centres\nPh 131 126 (24hrs)\nConsumer Medicines Information\nand adverse event reporting\n1300 MEDICINE\n(for consumers only)\nPh: 1300 633 424\nwww.1300medicine.com.au\nTherapeutic Goods Administration\nReport adverse drug reactions\nConsumer level recalls only\nPh: 1800 020 512\nTelephone Interpreter Service\nPh: 131 450 (24hrs)\nPBS Contacts\nContacts for Consumers\nContacts for Health Professionals\nContacts for Industry\nPBS Information Line\nFor further information on fees, patient contributions, benefit items and safety net\nthresholds — Free call 1800 020 613\nEnquiries from the media\n  Source: `pages/contact.html (http://www.pbs.gov.au/info/contacts/pbs-contacts)`\n- [Page 26]\nALIMENTARY TRACT AND METABOLISM\n22 Schedule of Pharmaceutical Benefits – May 2026\nHSD\n(Private)\nWhere the mean weekly volume of parenteral support in terms of mL per kg of body weight for 4 consecutive weeks has not\nbeen stated in an Initial treatment authority application for a patient yet to turn 18 years of age, provide in this authority\napplication both:\n(i) a known or estimated retrospective baseline value that would have applied to the patient immediately before commencing\ntreatment with this drug, and\n(ii) the current value (observed over a 4 week timeframe)\nProvide these values for a child only where mean weekly volume is to be used as an alternative response assessment to\nmean days of parenteral support per week.\n  Source: `other-pdfs/2026-05-01-general-schedule-Volume-2.pdf (http://www.pbs.gov.au/publication/schedule/2026/05/2026-05-01-general-schedule-Volume-2.pdf)`\n- If restriction is lengthy\nnew listing/change to listing) it may be paraphrased.)\nRAXTOZINAMERAN\nI.M. injection, suspension for injection containing\nraxtozinameran 30 micrograms\nNew vaccine - Prevention of\nTo request a National Immunisation Program listing for the\nprevention of coronavirus disease 2019 (COVID-19) caused by the\nComirnaty® Omicron XBB.1.5 coronavirus disease 2019 (COVID-19)\nSARS-CoV-2 virus in adults aged ≥ 18 years at increased risk of\ncaused by SARS-CoV-2\nsevere COVID-19 disease.\n  Source: `pbs/2025.pdf (http://www.pbs.gov.au/industry/listing/elements/pbac-meetings/agenda/pdf/2025/PBAC-Intracycle-meeting-agenda-DECEMBER-2025.pdf)`\n\n## Global Ideas and Case Study Inputs\n\n_No global-intelligence source text found yet. Run `CLAUDE/global-ideas-scraper.py <entity>` to populate case-study sources._\n\n## Source Artifacts Used\n\n- `pbs/2025.pdf` - pbs - http://www.pbs.gov.au/industry/listing/elements/pbac-meetings/agenda/pdf/2025/PBAC-Intracycle-meeting-agenda-DECEMBER-2025.pdf\n- `pbs/2026.pdf` - pbs - http://www.pbs.gov.au/publication/schedule/2026/05/2026-05-01-general-soc.pdf\n- `pages/about.html` - pages - http://www.pbs.gov.au/info/about-the-pbs\n- `pages/announcements-index.html` - pages - http://www.pbs.gov.au/files/pbac-membership/Statement-of-Expectations-for-the-PBAC-Chair-Professor-Robyn-Ward-2024.pdf\n- `pages/contact.html` - pages - http://www.pbs.gov.au/info/contacts/pbs-contacts\n- `pages/homepage.html` - pages - http://www.pbs.gov.au/info/industry/listing/participants/pbac\n- `pages/news-latest.html` - pages - http://www.pbs.gov.au/info/news\n- `pages/priorities-index.html` - pages - http://www.pbs.gov.au/info/industry/listing/elements/pbac-meetings/agenda\n- `pages/priorities-index__01.html` - pages - http://www.pbs.gov.au/info/industry/listing/elements/pbac-meetings/agenda\n- `pages/priorities-index__02.html` - pages - http://www.pbs.gov.au/info/industry/listing/elements/pbac-meetings/agenda/July-2026-PBAC-Meeting\n- `pages/priorities-index__03.html` - pages - http://www.pbs.gov.au/info/industry/listing/elements/pbac-meetings/agenda/may-2026-pbac-intracycle-meeting\n- `pages/priorities-index__04.html` - pages - http://www.pbs.gov.au/info/industry/listing/elements/pbac-meetings/agenda/march-2026-pbac-meeting\n- `pages/priorities-index__05.html` - pages - http://www.pbs.gov.au/info/industry/listing/elements/pbac-meetings/agenda/december-2025-pbac-intracycle-meeting\n- `pages/priorities-index__06.html` - pages - http://www.pbs.gov.au/info/industry/listing/elements/pbac-meetings/agenda/november-2025-pbac-meeting\n- `pages/priorities-index__07.html` - pages - http://www.pbs.gov.au/info/industry/listing/elements/pbac-meetings/agenda/september-2025-pbac-intracycle-meeting\n- `pages/priorities-index__08.html` - pages - http://www.pbs.gov.au/info/industry/listing/elements/pbac-meetings/agenda/july-2025-pbac-meeting\n- `pages/priorities-index__09.html` - pages - http://www.pbs.gov.au/info/industry/listing/elements/pbac-meetings/agenda/may-2025-pbac-meeting\n- `pages/priorities-index__10.html` - pages - http://www.pbs.gov.au/info/industry/listing/elements/pbac-meetings/agenda/march-2025-pbac-meeting\n- `pages/priorities-index__11.html` - pages - http://www.pbs.gov.au/info/industry/listing/elements/pbac-meetings/agenda/december-2024-pbac-intracycle-meeting\n- `pages/priorities-index__12.html` - pages - http://www.pbs.gov.au/info/industry/listing/elements/pbac-meetings/agenda/november-2024-pbac-meeting\n- `pages/priorities-index__13.html` - pages - http://www.pbs.gov.au/info/industry/listing/elements/pbac-meetings/agenda/september-2024-pbac-intracycle-meeting\n- `pages/priorities-index__14.html` - pages - http://www.pbs.gov.au/info/industry/listing/elements/pbac-meetings/agenda/july-2024-pbac-meeting\n- `pages/priorities-index__15.html` - pages - http://www.pbs.gov.au/info/industry/listing/elements/pbac-meetings/agenda/may-2024-pbac-intracycle-meeting\n- `pages/priorities-index__16.html` - pages - http://www.pbs.gov.au/info/industry/listing/elements/pbac-meetings/agenda/march-2024-pbac-meeting\n- `pages/priorities-index__17.html` - pages - http://www.pbs.gov.au/info/industry/listing/elements/pbac-meetings/agenda/december-2023-pbac-intracycle-meeting\n- `pages/priorities-index__18.html` - pages - http://www.pbs.gov.au/info/industry/listing/elements/pbac-meetings/agenda/november-2023-pbac-meeting\n- `pages/priorities-index__19.html` - pages - http://www.pbs.gov.au/info/industry/listing/elements/pbac-meetings/agenda/september-2023-pbac-intracycle-meeting\n- `pages/priorities-index__20.html` - pages - http://www.pbs.gov.au/info/industry/listing/elements/pbac-meetings/agenda/july-2023-pbac-meeting\n- `pages/priorities-index__21.html` - pages - http://www.pbs.gov.au/info/industry/listing/elements/pbac-meetings/agenda/may-2023-pbac-intracycle-meeting\n- `pages/priorities-index__22.html` - pages - http://www.pbs.gov.au/info/industry/listing/elements/pbac-meetings/agenda/march-2023-pbac-meeting\n- `pages/priorities-index__23.html` - pages - http://www.pbs.gov.au/info/industry/listing/elements/pbac-meetings/agenda/december-2022-pbac-intracycle-meeting\n- `pages/priorities-index__24.html` - pages - http://www.pbs.gov.au/info/industry/listing/elements/pbac-meetings/agenda/november-2022-pbac-meeting\n- `pages/priorities-index__25.html` - pages - http://www.pbs.gov.au/info/industry/listing/elements/pbac-meetings/agenda/september-2022-pbac-intracycle-meeting\n- `pages/priorities-index__26.html` - pages - http://www.pbs.gov.au/info/industry/listing/elements/pbac-meetings/agenda/july-2022-pbac-meeting\n- `pages/priorities-index__27.html` - pages - http://www.pbs.gov.au/info/industry/listing/elements/pbac-meetings/agenda/may-2022-pbac-intracycle-meeting\n- `pages/priorities-index__28.html` - pages - http://www.pbs.gov.au/info/industry/listing/elements/pbac-meetings/agenda/march-2022-pbac-meeting\n- `pages/priorities-index__29.html` - pages - http://www.pbs.gov.au/info/industry/listing/elements/pbac-meetings/agenda/dec-2021-pbac-intracycle-meeting\n- `pages/publications-index.html` - pages - http://www.pbs.gov.au/browse/publications\n- `pages/taskforces-index.html` - pages - http://www.pbs.gov.au/info/industry/listing/elements/pbac-meetings\n- `pages/taskforces-index__00.html` - pages - http://www.pbs.gov.au/info/browse/working-groups\n- `other-pdfs/2026-05-01-general-schedule-Volume-1.pdf` - other-pdfs - http://www.pbs.gov.au/publication/schedule/2026/05/2026-05-01-general-schedule-Volume-1.pdf\n- `other-pdfs/2026-05-01-general-schedule-Volume-2.pdf` - other-pdfs - http://www.pbs.gov.au/publication/schedule/2026/05/2026-05-01-general-schedule-Volume-2.pdf\n\n## Gaps To Fix\n\n- No corporate plan text source found.\n- No annual report text source found.\n- No global comparison/case-study sources found.",
  "legislation_md": "# Pharmaceutical Benefits Advisory Committee - Acts and Legislation Discovery\n\n**Generated at**: 2026-05-09T21:09:26.418833+00:00\n**Entity ID**: B-002589\n**Jurisdiction**: Commonwealth\n**Portfolio**: Health, Disability and Ageing\n\n> This is an evidence-based discovery list from scraped department material. A mention does not always mean the department administers the legislation; high-confidence and official register links should be reviewed.\n\n## Summary\n\n- Source files scanned: 42\n- Unique legislation references found: 7\n\n| Type | Count |\n|---|---:|\n| Act | 3 |\n| Regulation | 3 |\n| Rules | 1 |\n\n## Legislation References\n\n### National Health Act 1953\n\n**Type**: Act\n**Confidence**: high\n**Mentions**: 4\n**Register search**: https://www.legislation.gov.au/search?query=National+Health+Act+1953\n\n**Sources**:\n- `pages/about.html`\n- `pages/publications-index.html`\n- `other-pdfs/2026-05-01-general-schedule-Volume-1.pages.jsonl`\n- `other-pdfs/2026-05-01-general-schedule-Volume-2.pages.jsonl`\n\n**Evidence contexts**:\n- e conditions of use for the prescribing of PBS medicines\nDetailed consumer information for medicines that have been prescribed by your doctor\n or dentist\nWhat you can expect to pay for medicines.\nThe PBS has been in existence since 1948 and is governed by the National Health Act\n 1953 (Commonwealth).\nTop of page\nWho is eligible for the PBS?\nThe Scheme is available to all Australian residents who hold a current Medicare card.\nOverseas visitors from countries with which Australia has a\nReciprocal Health Care Agreement (RHCA)\nare also eligibl\n  Source: `pages/about.html`\n- ocess arrangements\nReviews\nReviews\nReports\nTrends in and drivers of Pharmaceutical Benefits Scheme expenditure (PDF 505 KB)\nTrends in and drivers of Pharmaceutical Benefits Scheme expenditure (Word 505 KB)\nReport to Parliament on the operation of s 89A of the National Health Act 1953 (‘Continued\n Dispensing’)\nDepartment of Health, Disability and Ageing\nPharmaceutical Benefits Scheme\n© Commonwealth of Australia\nABN: 83 605 426 759\nPBS Information\nAbout the PBS\nFrequently asked questions\nPharmaceutical Benefits Advisory Committee (PBAC)\nPub\n  Source: `pages/publications-index.html`\n- ral's Department, Robert Garran Offices,\nNational Circuit, Barton ACT 2600 or posted at http://www.ag.gov.au\nThis Schedule provides information on the arrangements for the prescribing and supply of pharmaceutical benefits. These\narrangements operate under the National Health Act 1953. However, at the time of printing, the relevant legislation giving\nauthority for the changes included in this issue of the Schedule may still be subject to the usual Parliamentary scrutiny. This\nbook is not a legal document, and, in cases of discrepancy, the\n  Source: `other-pdfs/2026-05-01-general-schedule-Volume-1.pages.jsonl`\n- ral's Department, Robert Garran Offices,\nNational Circuit, Barton ACT 2600 or posted at http://www.ag.gov.au\nThis Schedule provides information on the arrangements for the prescribing and supply of pharmaceutical benefits. These\narrangements operate under the National Health Act 1953. However, at the time of printing, the relevant legislation giving\nauthority for the changes included in this issue of the Schedule may still be subject to the usual Parliamentary scrutiny. This\nbook is not a legal document, and, in cases of discrepancy, the\n  Source: `other-pdfs/2026-05-01-general-schedule-Volume-2.pages.jsonl`\n\n### National Health (Pharmaceutical Benefits) Amendment Regulation 2012\n\n**Type**: Regulation\n**Confidence**: medium\n**Mentions**: 1\n**Register search**: https://www.legislation.gov.au/search?query=National+Health+%28Pharmaceutical+Benefits%29+Amendment+Regulation+2012\n\n**Sources**:\n- `pages/news-latest.html`\n\n**Evidence contexts**:\n- mpact of PBS Cost Recovery -19 September 2012\nReport to Parliament – Pharmaceutical Industry Discussion Group (PIDG) - 13 September\n 2012\nPBS Website Update - 1 September 2012\nTop of page\nAugust 2012\n2012 Changes to PBS Pricing Arrangements – National Health (Pharmaceutical Benefits)\n Amendment Regulation 2012 (No. 4) – 24 August 2012\nSubmissions to the Review of Pharmaceutical Benefits Scheme Listed Anti-dementia Drugs\n to Treat Alzheimers Disease - 24 August 2012\nGrowth Hormone News Update - Short Dated Stock - 7 August 2012\nIncreased prices to consumers for 85 b\n  Source: `pages/news-latest.html`\n\n### National Health (Pharmaceutical Benefits) Regulations 2017\n\n**Type**: Regulation\n**Confidence**: medium\n**Mentions**: 1\n**Register search**: https://www.legislation.gov.au/search?query=National+Health+%28Pharmaceutical+Benefits%29+Regulations+2017\n\n**Sources**:\n- `pages/news-latest.html`\n\n**Evidence contexts**:\n- ics report for 2022-23\n - 19 April 2024\nUpdates to the HTA Policy and Methods Review Reference Committee – 15 April 2024\nPBAC Public Summary Documents – December 2023 meeting - 5 April 2024\nAgenda for the July 2024 PBAC meeting – 3 April 2024\nNational Health (Pharmaceutical Benefits) Regulations 2017 amendments - 3 April 2024\nPublic Consultation: Draft 2024-25 Cost Recovery Implementation Statement (CRIS) for\n listing medicines on the PBS and designated vaccines on the NIP - 2 April 2024\n1 April 2024 designated brand list – minimum stockholding requiremen\n  Source: `pages/news-latest.html`\n\n### National Health Amendment (Pharmaceutical Benefits) Act 2017\n\n**Type**: Act\n**Confidence**: medium\n**Mentions**: 1\n**Register search**: https://www.legislation.gov.au/search?query=National+Health+Amendment+%28Pharmaceutical+Benefits%29+Act+2017\n\n**Sources**:\n- `pages/news-latest.html`\n\n**Evidence contexts**:\n- wareness Initiative update - 1 April 2017\nPBS Website Update - 1 April 2017\nMarch 2017\nAdvice for approved pharmacists supplying PBS medicines to patients in areas affected\n by Ex-Tropical Cyclone Debbie – March 2017 - 30 March 2017\nNational Health Amendment (Pharmaceutical Benefits) Act 2017 - 29 March 2017\nPost-Market Review of the Use of Biologics in the Treatment of Severe Chronic Plaque\n Psoriasis – Public Consultation Process - 28 March 2017\nPublic Summary Document (PSD) for pembrolizumab (NSCLC) - November 2016 PBAC meeting\n - 23 March 2017\n  Source: `pages/news-latest.html`\n\n### Budget and Other Measures) Act 2018\n\n**Type**: Act\n**Confidence**: low\n**Mentions**: 1\n**Register search**: https://www.legislation.gov.au/search?query=Budget+and+Other+Measures%29+Act+2018\n\n**Sources**:\n- `pages/news-latest.html`\n\n**Evidence contexts**:\n- isation Sub Committee (DUSC) Utilisation Analysis Public Release Documents\n - 2 March 2018\nPBS Website Update - 1 March 2018\nFebruary 2018\nNusinersen Stakeholder Meeting Outcome Statement - 23 February 2018\nNational Health Amendment (Pharmaceutical Benefits – Budget and Other Measures) Act\n 2018 - 23 February 2018\nAugust 2018 PBAC special meeting - 19 February 2018\nRecommendations made by the PBAC - December 2017\nBiosimilar Awareness Initiative - Literature Review - 2 February 2018\nPBS Website Update - 1 February 2018\nJanuary 2018\nPost-market Review\n  Source: `pages/news-latest.html`\n\n### Cost Recovery) Regulations 2009\n\n**Type**: Regulation\n**Confidence**: low\n**Mentions**: 1\n**Register search**: https://www.legislation.gov.au/search?query=Cost+Recovery%29+Regulations+2009\n\n**Sources**:\n- `pages/news-latest.html`\n\n**Evidence contexts**:\n- 2\nRemake of National Health (Supply of Pharmaceutical Benefits – Under Co-payment Data\n and Claims for Payment) Rules 2022 - 25 May 2022\nReview of discount rate in the PBAC guidelines - 25 May 2022\nRemake of the National Health (Pharmaceuticals and Vaccines – Cost Recovery) Regulations\n 2009 - 11 May 2022\nUpdated Agenda for the July 2022 PBAC Meeting - 6 May 2022\nPBS Website Update - 1 May 2022\nApril 2022\nAgenda Update for the May 2022 PBAC Intracycle meeting - 29 April 2022\nRecommendations made by the PBAC - March 2022 - 22 April 2022\nPBAC Publi\n  Source: `pages/news-latest.html`\n\n### Under Co-payment Data and Claims for Payment) Rules 2022\n\n**Type**: Rules\n**Confidence**: low\n**Mentions**: 1\n**Register search**: https://www.legislation.gov.au/search?query=Under+Co-payment+Data+and+Claims+for+Payment%29+Rules+2022\n\n**Sources**:\n- `pages/news-latest.html`\n\n**Evidence contexts**:\n- 1 July 2022 - 16\n June 2022\nUpdated Price Disclosure Guidelines, Price Disclosure webpages and Price Disclosure\n Dispute Resolution Process - 8 June 2022\nPBS Website Update - 1 June 2022\nMay 2022\nRemake of National Health (Supply of Pharmaceutical Benefits – Under Co-payment Data\n and Claims for Payment) Rules 2022 - 25 May 2022\nReview of discount rate in the PBAC guidelines - 25 May 2022\nRemake of the National Health (Pharmaceuticals and Vaccines – Cost Recovery) Regulations\n 2009 - 11 May 2022\nUpdated Agenda for the July 2022 PBAC Meeting - 6 May 2022\nPBS Website Upda\n  Source: `pages/news-latest.html`\n\n## Files Scanned\n\n- `pages/about.html` (page)\n- `pages/announcements-index.html` (page)\n- `pages/contact.html` (page)\n- `pages/homepage.html` (page)\n- `pages/news-latest.html` (page)\n- `pages/priorities-index.html` (page)\n- `pages/priorities-index__01.html` (page)\n- `pages/priorities-index__02.html` (page)\n- `pages/priorities-index__03.html` (page)\n- `pages/priorities-index__04.html` (page)\n- `pages/priorities-index__05.html` (page)\n- `pages/priorities-index__06.html` (page)\n- `pages/priorities-index__07.html` (page)\n- `pages/priorities-index__08.html` (page)\n- `pages/priorities-index__09.html` (page)\n- `pages/priorities-index__10.html` (page)\n- `pages/priorities-index__11.html` (page)\n- `pages/priorities-index__12.html` (page)\n- `pages/priorities-index__13.html` (page)\n- `pages/priorities-index__14.html` (page)\n- `pages/priorities-index__15.html` (page)\n- `pages/priorities-index__16.html` (page)\n- `pages/priorities-index__17.html` (page)\n- `pages/priorities-index__18.html` (page)\n- `pages/priorities-index__19.html` (page)\n- `pages/priorities-index__20.html` (page)\n- `pages/priorities-index__21.html` (page)\n- `pages/priorities-index__22.html` (page)\n- `pages/priorities-index__23.html` (page)\n- `pages/priorities-index__24.html` (page)\n- `pages/priorities-index__25.html` (page)\n- `pages/priorities-index__26.html` (page)\n- `pages/priorities-index__27.html` (page)\n- `pages/priorities-index__28.html` (page)\n- `pages/priorities-index__29.html` (page)\n- `pages/publications-index.html` (page)\n- `pages/taskforces-index.html` (page)\n- `pages/taskforces-index__00.html` (page)\n- `other-pdfs/2026-05-01-general-schedule-Volume-1.pages.jsonl` (pdf_pages)\n- `other-pdfs/2026-05-01-general-schedule-Volume-2.pages.jsonl` (pdf_pages)\n- `pbs/2025.pages.jsonl` (pdf_pages)\n- `pbs/2026.pages.jsonl` (pdf_pages)",
  "global_initiatives_md": null,
  "strategy": {
    "reporting_period": "2024-25",
    "corporate_plan_period": "2025-26",
    "vision": null,
    "vision_source_page": null,
    "purposes": null,
    "purposes_source_page": null,
    "how_we_deliver": null,
    "how_we_deliver_source_page": null,
    "government_priorities": [],
    "outcomes": [],
    "values": [],
    "values_framework_name": null,
    "kpi_targets_2025_26": [],
    "kpi_results_2024_25": [],
    "_source_urls": {
      "annual_report_url": "",
      "corporate_plan_url": ""
    }
  },
  "ideas": [
    {
      "entity_id": "B-002589",
      "entity_name": "Pharmaceutical Benefits Advisory Committee",
      "folder_name": "Pharmaceutical-Benefits-Advisory-Committee",
      "category": "Case Processing",
      "scale": "small",
      "title": "Triage queue for stuck or ageing cases",
      "idea": "Use existing case data to flag ageing, duplicate, incomplete, or high-risk cases for earlier intervention.",
      "quote": "The authority application must be made in writing and must include:\n(a) details of the proposed prescription(s); and\n(b) a completed authority application form relevant to the indication and treatment phase (the latest version is located on the\nwebsite specified in the Administrative Advice).\nteduglutide 5 mg injection [28 vials] (&) inert substance diluent [28 x 0.5 mL syringes], 1 pack\n11806J Max.Qty Packs No. of Rpts Premium $ DPMQ $ Brand Name and Manufacturer\n1 5 ..",
      "impact": "High",
      "effort": "Low",
      "proof": "Evidence-backed",
      "beneficiaries": "Applicants / case officers",
      "source": "other-pdfs/2026-05-01-general-schedule-Volume-2.pdf (http://www.pbs.gov.au/publication/schedule/2026/05/2026-05-01-general-schedule-Volume-2.pdf)",
      "implementation": [
        "Pick one high-volume process or document family.",
        "Name an owner and baseline current volume, time, cost, and satisfaction.",
        "Run a 4-8 week pilot with clear before/after metrics.",
        "Publish lessons and decide whether to scale."
      ],
      "risks": [
        "Privacy and data quality",
        "Change fatigue",
        "Unclear accountability"
      ]
    },
    {
      "entity_id": "B-002589",
      "entity_name": "Pharmaceutical Benefits Advisory Committee",
      "folder_name": "Pharmaceutical-Benefits-Advisory-Committee",
      "category": "Case Processing",
      "scale": "large",
      "title": "End-to-end case processing redesign",
      "idea": "Redesign the case pathway around risk-based triage, reusable evidence, and automated eligibility checks.",
      "quote": "The authority application must be made in writing and must include:\n(a) details of the proposed prescription(s); and\n(b) a completed authority application form relevant to the indication and treatment phase (the latest version is located on the\nwebsite specified in the Administrative Advice).\nteduglutide 5 mg injection [28 vials] (&) inert substance diluent [28 x 0.5 mL syringes], 1 pack\n11806J Max.Qty Packs No. of Rpts Premium $ DPMQ $ Brand Name and Manufacturer\n1 5 ..",
      "impact": "Very High",
      "effort": "High",
      "proof": "Evidence-backed",
      "beneficiaries": "Applicants / case officers",
      "source": "other-pdfs/2026-05-01-general-schedule-Volume-2.pdf (http://www.pbs.gov.au/publication/schedule/2026/05/2026-05-01-general-schedule-Volume-2.pdf)",
      "implementation": [
        "Create a senior responsible owner and cross-functional delivery team.",
        "Map legislation, data, privacy, procurement, cyber, and workforce constraints.",
        "Co-design with users and frontline staff before technology selection.",
        "Stage delivery through pilots, benefits tracking, and public reporting."
      ],
      "risks": [
        "Privacy and data quality",
        "Change fatigue",
        "Unclear accountability"
      ]
    },
    {
      "entity_id": "B-002589",
      "entity_name": "Pharmaceutical Benefits Advisory Committee",
      "folder_name": "Pharmaceutical-Benefits-Advisory-Committee",
      "category": "Citizen Services",
      "scale": "small",
      "title": "Plain-language service pages and proactive status updates",
      "idea": "Rewrite high-volume pages and letters into plain language, add status notifications, and measure contact reduction.",
      "quote": "[pages 28,29]\ns)\nAlternatively, applications for authority to prescribe can be submitted online using the form upload facility in Health\nProfessional Online Services (HPOS) at www.servicesaustralia.gov.au/hpos\nOr mailed to:\nServices Australia\nComplex Drugs\nReply Paid 9826\nHOBART TAS 7001\nAuthority required\nSevere aplastic anaemia\nTreatment Phase: Initial treatment - Second line treatment\nClinical criteria:\n• The condition must be severe aplastic anaemia, AND\n• Patient must not have achieved an adequate response to prior immunosuppressive therapy including anti-thymocyte\nantibody and ciclosporin; OR\n• Patient must have relapsed following prior immunosuppressive therapy including anti-thymocyte antibody and ciclosporin,\nAND\n• Patient must not receive more than 16 weeks of treatment under this restriction.",
      "impact": "High",
      "effort": "Low",
      "proof": "Evidence-backed",
      "beneficiaries": "Citizens / service users",
      "source": "other-pdfs/2026-05-01-general-schedule-Volume-2.pdf (http://www.pbs.gov.au/publication/schedule/2026/05/2026-05-01-general-schedule-Volume-2.pdf)",
      "implementation": [
        "Pick one high-volume process or document family.",
        "Name an owner and baseline current volume, time, cost, and satisfaction.",
        "Run a 4-8 week pilot with clear before/after metrics.",
        "Publish lessons and decide whether to scale."
      ],
      "risks": [
        "Privacy and data quality",
        "Change fatigue",
        "Unclear accountability",
        "Digital exclusion",
        "Low public trust if feedback is not acted on"
      ]
    },
    {
      "entity_id": "B-002589",
      "entity_name": "Pharmaceutical Benefits Advisory Committee",
      "folder_name": "Pharmaceutical-Benefits-Advisory-Committee",
      "category": "Citizen Services",
      "scale": "large",
      "title": "Single front door for life-event based services",
      "idea": "Bundle services around life events so citizens can complete related steps across agencies in one journey.",
      "quote": "[pages 28,29]\ns)\nAlternatively, applications for authority to prescribe can be submitted online using the form upload facility in Health\nProfessional Online Services (HPOS) at www.servicesaustralia.gov.au/hpos\nOr mailed to:\nServices Australia\nComplex Drugs\nReply Paid 9826\nHOBART TAS 7001\nAuthority required\nSevere aplastic anaemia\nTreatment Phase: Initial treatment - Second line treatment\nClinical criteria:\n• The condition must be severe aplastic anaemia, AND\n• Patient must not have achieved an adequate response to prior immunosuppressive therapy including anti-thymocyte\nantibody and ciclosporin; OR\n• Patient must have relapsed following prior immunosuppressive therapy including anti-thymocyte antibody and ciclosporin,\nAND\n• Patient must not receive more than 16 weeks of treatment under this restriction.",
      "impact": "Very High",
      "effort": "High",
      "proof": "Evidence-backed",
      "beneficiaries": "Citizens / service users",
      "source": "other-pdfs/2026-05-01-general-schedule-Volume-2.pdf (http://www.pbs.gov.au/publication/schedule/2026/05/2026-05-01-general-schedule-Volume-2.pdf)",
      "implementation": [
        "Create a senior responsible owner and cross-functional delivery team.",
        "Map legislation, data, privacy, procurement, cyber, and workforce constraints.",
        "Co-design with users and frontline staff before technology selection.",
        "Stage delivery through pilots, benefits tracking, and public reporting."
      ],
      "risks": [
        "Privacy and data quality",
        "Change fatigue",
        "Unclear accountability",
        "Digital exclusion",
        "Low public trust if feedback is not acted on"
      ]
    },
    {
      "entity_id": "B-002589",
      "entity_name": "Pharmaceutical Benefits Advisory Committee",
      "folder_name": "Pharmaceutical-Benefits-Advisory-Committee",
      "category": "Risk & Assurance",
      "scale": "small",
      "title": "Recommendation tracker for audits, reviews, and inquiries",
      "idea": "Publish a single internal tracker for audit/review recommendations, owners, due dates, and implementation evidence.",
      "quote": "[pages 42,43]\nt must be assessed for the risks/benefits of a step-down in dosing from a high dose PPI administered twice daily,\nwith the determination being that the risks outweigh the benefits; treatment is for: (2) maintenance treatment; OR\n• Patient must have trialled a step-down in dosing, yet symptoms have re-emerged/worsened; treatment is for: (3) re-\nestablishment of symptom control; OR\n• Patient must have trialled a step-down in dosing, with symptoms adequately managed with once daily dosing; treatment\nis for: (2) maintenance treatment, but with the quantity sought in this authority application being up to 1 pack per\ndispensing.",
      "impact": "High",
      "effort": "Low",
      "proof": "Evidence-backed",
      "beneficiaries": "Executives / assurance teams",
      "source": "other-pdfs/2026-05-01-general-schedule-Volume-1.pdf (http://www.pbs.gov.au/publication/schedule/2026/05/2026-05-01-general-schedule-Volume-1.pdf)",
      "implementation": [
        "Pick one high-volume process or document family.",
        "Name an owner and baseline current volume, time, cost, and satisfaction.",
        "Run a 4-8 week pilot with clear before/after metrics.",
        "Publish lessons and decide whether to scale."
      ],
      "risks": [
        "Privacy and data quality",
        "Change fatigue",
        "Unclear accountability",
        "Regulatory capture",
        "Over-automation of judgement"
      ]
    },
    {
      "entity_id": "B-002589",
      "entity_name": "Pharmaceutical Benefits Advisory Committee",
      "folder_name": "Pharmaceutical-Benefits-Advisory-Committee",
      "category": "Risk & Assurance",
      "scale": "large",
      "title": "Integrated assurance and lessons-learned system",
      "idea": "Create an assurance system that connects audit findings, risk registers, delivery reviews, and investment decisions.",
      "quote": "[pages 42,43]\nt must be assessed for the risks/benefits of a step-down in dosing from a high dose PPI administered twice daily,\nwith the determination being that the risks outweigh the benefits; treatment is for: (2) maintenance treatment; OR\n• Patient must have trialled a step-down in dosing, yet symptoms have re-emerged/worsened; treatment is for: (3) re-\nestablishment of symptom control; OR\n• Patient must have trialled a step-down in dosing, with symptoms adequately managed with once daily dosing; treatment\nis for: (2) maintenance treatment, but with the quantity sought in this authority application being up to 1 pack per\ndispensing.",
      "impact": "Very High",
      "effort": "High",
      "proof": "Evidence-backed",
      "beneficiaries": "Executives / assurance teams",
      "source": "other-pdfs/2026-05-01-general-schedule-Volume-1.pdf (http://www.pbs.gov.au/publication/schedule/2026/05/2026-05-01-general-schedule-Volume-1.pdf)",
      "implementation": [
        "Create a senior responsible owner and cross-functional delivery team.",
        "Map legislation, data, privacy, procurement, cyber, and workforce constraints.",
        "Co-design with users and frontline staff before technology selection.",
        "Stage delivery through pilots, benefits tracking, and public reporting."
      ],
      "risks": [
        "Privacy and data quality",
        "Change fatigue",
        "Unclear accountability",
        "Regulatory capture",
        "Over-automation of judgement"
      ]
    },
    {
      "entity_id": "B-002589",
      "entity_name": "Pharmaceutical Benefits Advisory Committee",
      "folder_name": "Pharmaceutical-Benefits-Advisory-Committee",
      "category": "Staff Productivity",
      "scale": "small",
      "title": "Reusable briefing and summary assistant for internal documents",
      "idea": "Create controlled templates for summarising reports, submissions, minutes, and ministerial briefs.",
      "quote": "[pages 56,57]\nment must be: (i) the sole PBS-subsidised proton pump inhibitor (PPI) for this condition, (ii) the sole strength of\nthis PPI, (iii) the sole form of PPI, AND\n• Patient must must have symptoms inadequately controlled with each of: (i) a standard dose proton pump inhibitor (PPI)\nadministered once daily, (ii) a low dose PPI administered twice daily; treatment is for: (1) establishment of symptom\ncontrol; OR\n• Patient must be assessed for the risks/benefits of a step-down in dosing from standard dose PPI administered twice daily,\nwith the determination being that the risks outweigh the benefits; treatment is for: (2) maintenance treatment; OR\n• Patient must have trialled a step-down in dosing, yet symptoms have re-emerged/worsened; treatment is for: (3) re-\nestablishment of symptom control; OR",
      "impact": "High",
      "effort": "Low",
      "proof": "Evidence-backed",
      "beneficiaries": "APS staff / executives",
      "source": "other-pdfs/2026-05-01-general-schedule-Volume-1.pdf (http://www.pbs.gov.au/publication/schedule/2026/05/2026-05-01-general-schedule-Volume-1.pdf)",
      "implementation": [
        "Pick one high-volume process or document family.",
        "Name an owner and baseline current volume, time, cost, and satisfaction.",
        "Run a 4-8 week pilot with clear before/after metrics.",
        "Publish lessons and decide whether to scale."
      ],
      "risks": [
        "Privacy and data quality",
        "Change fatigue",
        "Unclear accountability",
        "Sensitive information leakage",
        "Inconsistent quality of generated drafts"
      ]
    },
    {
      "entity_id": "B-002589",
      "entity_name": "Pharmaceutical Benefits Advisory Committee",
      "folder_name": "Pharmaceutical-Benefits-Advisory-Committee",
      "category": "Staff Productivity",
      "scale": "large",
      "title": "Department-wide knowledge and briefing platform",
      "idea": "Build a secure knowledge platform that lets staff search, summarise, and cite approved departmental material.",
      "quote": "[pages 56,57]\nment must be: (i) the sole PBS-subsidised proton pump inhibitor (PPI) for this condition, (ii) the sole strength of\nthis PPI, (iii) the sole form of PPI, AND\n• Patient must must have symptoms inadequately controlled with each of: (i) a standard dose proton pump inhibitor (PPI)\nadministered once daily, (ii) a low dose PPI administered twice daily; treatment is for: (1) establishment of symptom\ncontrol; OR\n• Patient must be assessed for the risks/benefits of a step-down in dosing from standard dose PPI administered twice daily,\nwith the determination being that the risks outweigh the benefits; treatment is for: (2) maintenance treatment; OR\n• Patient must have trialled a step-down in dosing, yet symptoms have re-emerged/worsened; treatment is for: (3) re-\nestablishment of symptom control; OR",
      "impact": "Very High",
      "effort": "High",
      "proof": "Evidence-backed",
      "beneficiaries": "APS staff / executives",
      "source": "other-pdfs/2026-05-01-general-schedule-Volume-1.pdf (http://www.pbs.gov.au/publication/schedule/2026/05/2026-05-01-general-schedule-Volume-1.pdf)",
      "implementation": [
        "Create a senior responsible owner and cross-functional delivery team.",
        "Map legislation, data, privacy, procurement, cyber, and workforce constraints.",
        "Co-design with users and frontline staff before technology selection.",
        "Stage delivery through pilots, benefits tracking, and public reporting."
      ],
      "risks": [
        "Privacy and data quality",
        "Change fatigue",
        "Unclear accountability",
        "Sensitive information leakage",
        "Inconsistent quality of generated drafts"
      ]
    },
    {
      "entity_id": "B-002589",
      "entity_name": "Pharmaceutical Benefits Advisory Committee",
      "folder_name": "Pharmaceutical-Benefits-Advisory-Committee",
      "category": "Data & Performance",
      "scale": "small",
      "title": "KPI evidence register with named owners",
      "idea": "Create a simple register mapping each KPI to source data, owner, frequency, target, and last result.",
      "quote": "Authority Required (STREAMLINED)\n18113\nChronic heart failure\nClinical criteria:\n• The condition must be stable for the prescriber to consider the listed maximum quantity of this medicine suitable for this\npatient, AND\n• Patient must be symptomatic with NYHA classes II, III or IV prior to initiating treatment with this drug, AND\n• Patient must have a documented left ventricular ejection fraction (LVEF) of greater than 40%, AND\n• Patient must have documented evidence of structural changes in the heart on echocardiography that would be expected\nto cause diastolic dysfunction (e.g. left ventricular hypertrophy), AND\n• Patient must have documented evidence of at least one of the following:\n(i) diastolic dysfunction with high filling pressure on echocardiography, stress echocardiography or cardiac\ncatheterisation;",
      "impact": "High",
      "effort": "Low",
      "proof": "Evidence-backed",
      "beneficiaries": "Executives / Parliament / public",
      "source": "pbs/2026.pdf (http://www.pbs.gov.au/publication/schedule/2026/05/2026-05-01-general-soc.pdf)",
      "implementation": [
        "Pick one high-volume process or document family.",
        "Name an owner and baseline current volume, time, cost, and satisfaction.",
        "Run a 4-8 week pilot with clear before/after metrics.",
        "Publish lessons and decide whether to scale."
      ],
      "risks": [
        "Privacy and data quality",
        "Change fatigue",
        "Unclear accountability"
      ]
    },
    {
      "entity_id": "B-002589",
      "entity_name": "Pharmaceutical Benefits Advisory Committee",
      "folder_name": "Pharmaceutical-Benefits-Advisory-Committee",
      "category": "Data & Performance",
      "scale": "large",
      "title": "Outcome dashboard linking budget, delivery, and public impact",
      "idea": "Build a public-facing outcome dashboard showing spend, outputs, outcomes, and delivery confidence.",
      "quote": "Authority Required (STREAMLINED)\n18113\nChronic heart failure\nClinical criteria:\n• The condition must be stable for the prescriber to consider the listed maximum quantity of this medicine suitable for this\npatient, AND\n• Patient must be symptomatic with NYHA classes II, III or IV prior to initiating treatment with this drug, AND\n• Patient must have a documented left ventricular ejection fraction (LVEF) of greater than 40%, AND\n• Patient must have documented evidence of structural changes in the heart on echocardiography that would be expected\nto cause diastolic dysfunction (e.g. left ventricular hypertrophy), AND\n• Patient must have documented evidence of at least one of the following:\n(i) diastolic dysfunction with high filling pressure on echocardiography, stress echocardiography or cardiac\ncatheterisation;",
      "impact": "Very High",
      "effort": "High",
      "proof": "Evidence-backed",
      "beneficiaries": "Executives / Parliament / public",
      "source": "pbs/2026.pdf (http://www.pbs.gov.au/publication/schedule/2026/05/2026-05-01-general-soc.pdf)",
      "implementation": [
        "Create a senior responsible owner and cross-functional delivery team.",
        "Map legislation, data, privacy, procurement, cyber, and workforce constraints.",
        "Co-design with users and frontline staff before technology selection.",
        "Stage delivery through pilots, benefits tracking, and public reporting."
      ],
      "risks": [
        "Privacy and data quality",
        "Change fatigue",
        "Unclear accountability"
      ]
    },
    {
      "entity_id": "B-002589",
      "entity_name": "Pharmaceutical Benefits Advisory Committee",
      "folder_name": "Pharmaceutical-Benefits-Advisory-Committee",
      "category": "Citizen Participation",
      "scale": "small",
      "title": "Consultation feedback summaries with response tracking",
      "idea": "Summarise consultation submissions by theme and publish what changed in response.",
      "quote": "[Page 13]\n13044M Azacitidine Sandoz, SZ – AZACITIDINE, azacitidine 100 mg injection, 1 vial\nHighly Specialised Drugs Program (Community Access)\nDeletions\nDeletion – Brand\n11501H Octreotide Depot, TB – OCTREOTIDE, octreotide 10 mg modified release injection [1 vial] (&) inert substance\ndiluent [2 mL syringe], 1 pack\n11537F Octreotide Depot, TB – OCTREOTIDE, octreotide 20 mg modified release injection [1 vial] (&) inert substance\ndiluent [2 mL syringe], 1 pack\n11512X Octreotide Depot, TB – OCTREOTIDE, octreotide 30 mg modified release injection [1 vial] (&) inert substance\ndiluent [2 mL syringe], 1 pack\n11896D Octreotide Depot, TB – OCTREOTIDE, octreotide 30 mg modified release injection [1 vial] (&) inert substance\ndiluent [2 mL syringe], 1 pack\nDeletion – Equivalence Indicator",
      "impact": "High",
      "effort": "Low",
      "proof": "Evidence-backed",
      "beneficiaries": "Citizens / stakeholders / policy teams",
      "source": "pbs/2026.pdf (http://www.pbs.gov.au/publication/schedule/2026/05/2026-05-01-general-soc.pdf)",
      "implementation": [
        "Pick one high-volume process or document family.",
        "Name an owner and baseline current volume, time, cost, and satisfaction.",
        "Run a 4-8 week pilot with clear before/after metrics.",
        "Publish lessons and decide whether to scale."
      ],
      "risks": [
        "Privacy and data quality",
        "Change fatigue",
        "Unclear accountability",
        "Digital exclusion",
        "Low public trust if feedback is not acted on"
      ]
    },
    {
      "entity_id": "B-002589",
      "entity_name": "Pharmaceutical Benefits Advisory Committee",
      "folder_name": "Pharmaceutical-Benefits-Advisory-Committee",
      "category": "Citizen Participation",
      "scale": "large",
      "title": "Always-on policy participation platform",
      "idea": "Create a standing participation platform where citizens and stakeholders can propose, vote, and track ideas.",
      "quote": "[Page 13]\n13044M Azacitidine Sandoz, SZ – AZACITIDINE, azacitidine 100 mg injection, 1 vial\nHighly Specialised Drugs Program (Community Access)\nDeletions\nDeletion – Brand\n11501H Octreotide Depot, TB – OCTREOTIDE, octreotide 10 mg modified release injection [1 vial] (&) inert substance\ndiluent [2 mL syringe], 1 pack\n11537F Octreotide Depot, TB – OCTREOTIDE, octreotide 20 mg modified release injection [1 vial] (&) inert substance\ndiluent [2 mL syringe], 1 pack\n11512X Octreotide Depot, TB – OCTREOTIDE, octreotide 30 mg modified release injection [1 vial] (&) inert substance\ndiluent [2 mL syringe], 1 pack\n11896D Octreotide Depot, TB – OCTREOTIDE, octreotide 30 mg modified release injection [1 vial] (&) inert substance\ndiluent [2 mL syringe], 1 pack\nDeletion – Equivalence Indicator",
      "impact": "High",
      "effort": "High",
      "proof": "Evidence-backed",
      "beneficiaries": "Citizens / stakeholders / policy teams",
      "source": "pbs/2026.pdf (http://www.pbs.gov.au/publication/schedule/2026/05/2026-05-01-general-soc.pdf)",
      "implementation": [
        "Create a senior responsible owner and cross-functional delivery team.",
        "Map legislation, data, privacy, procurement, cyber, and workforce constraints.",
        "Co-design with users and frontline staff before technology selection.",
        "Stage delivery through pilots, benefits tracking, and public reporting."
      ],
      "risks": [
        "Privacy and data quality",
        "Change fatigue",
        "Unclear accountability",
        "Digital exclusion",
        "Low public trust if feedback is not acted on"
      ]
    }
  ],
  "legislation_administered": [],
  "artifacts": [
    {
      "category": "pbs",
      "year": "2026",
      "url": "http://www.pbs.gov.au/publication/schedule/2026/05/2026-05-01-general-soc.pdf",
      "file": "pbs/2026.pdf",
      "bytes": 371591,
      "link_text": "Schedule of Pharmaceutical Benefits (Summary of Changes) (PDF 2MB)"
    },
    {
      "category": "pbs",
      "year": "2025",
      "url": "http://www.pbs.gov.au/industry/listing/elements/pbac-meetings/agenda/pdf/2025/PBAC-Intracycle-meeting-agenda-DECEMBER-2025.pdf",
      "file": "pbs/2025.pdf",
      "bytes": 275754,
      "link_text": "December 2025 PBAC Intracycle Meeting (PDF 254KB)"
    },
    {
      "category": "other-pdfs",
      "year": "2026",
      "url": "http://www.pbs.gov.au/publication/schedule/2026/05/2026-05-01-general-schedule-Volume-1.pdf",
      "file": "other-pdfs/2026-05-01-general-schedule-Volume-1.pdf",
      "bytes": 14155691,
      "link_text": "Schedule of Pharmaceutical Benefits (Volume 1 - General Schedule) (PDF 20MB)"
    },
    {
      "category": "other-pdfs",
      "year": "2026",
      "url": "http://www.pbs.gov.au/publication/schedule/2026/05/2026-05-01-general-schedule-Volume-2.pdf",
      "file": "other-pdfs/2026-05-01-general-schedule-Volume-2.pdf",
      "bytes": 9898431,
      "link_text": "Schedule of Pharmaceutical Benefits (Volume 2 - Section 100) (PDF 10MB)"
    }
  ],
  "_meta": {
    "snapshot_built_at": "2026-05-13T11:02:59+00:00",
    "strategy_brief_meta": {
      "model": "nova-micro",
      "folder": "Pharmaceutical-Benefits-Advisory-Committee",
      "annual_report": {
        "file": null,
        "url": "",
        "year": null
      },
      "corporate_plan": {
        "file": "other-pdfs\\2026-05-01-general-schedule-Volume-1.txt",
        "url": "http://www.pbs.gov.au/publication/schedule/2026/05/2026-05-01-general-schedule-Volume-1.pdf",
        "year": "2026-05-01-general-schedule-Volume-1"
      },
      "usage": {
        "input_tokens": 18237,
        "output_tokens": 155,
        "total_tokens": 18392,
        "model": "nova-micro"
      },
      "cost_usd": 0.0006599950000000001,
      "elapsed_seconds": 8.78,
      "generated_at": "2026-05-13T05:18:18+00:00"
    },
    "ideas_manifest": {
      "entity_id": "B-002589",
      "entity_name": "Pharmaceutical Benefits Advisory Committee",
      "folder_name": "Pharmaceutical-Benefits-Advisory-Committee",
      "generated_at": "2026-05-09T23:05:37.825944+00:00",
      "idea_count": 12,
      "markdown": "ideas/Pharmaceutical-Benefits-Advisory-Committee_ideas.md",
      "jsonl": "ideas/ideas.jsonl",
      "inputs": [
        "Pharmaceutical-Benefits-Advisory-Committee_strategy-overview.md",
        "strategy-evidence.json",
        "global-intelligence/source-manifest.json"
      ]
    },
    "global_intel_meta": null
  }
}